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ABSTRACT
Computational design of protein-protein interaction specificity is a powerful tool to examine and
expand our understanding about how protein sequence determines interaction specificity. It also
has many applications in basic bioscience and biotechnology. One of the major challenges for
design is that current scoring functions relying on general physical principles do not always
make reliable predictions about interaction specificity. In this thesis I described application of
two approaches to address this problem. The first approach sought to improve scoring functions
with experimental interaction specificity data related to the protein family of design interest. I
used this approach to design inhibitor peptides against the viral bZIP protein BZLF 1. Specificity
against design self-interaction was considered in the study. The second approach exploited the
power of experimental library screening to characterize a large number of designed sequences at
once, increasing the overall probability of identifying successful designs. I presented a novel
framework for such library design approach and applied it to the design of anti-apoptotic Bcl-2
proteins with novel interaction specificity toward BH3 peptides. Finally I proposed how these
two approaches can be combined together to further enhance our design capabilities.
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Chapter 1
Introduction
Protein-protein interactions play important roles in virtually every aspect of cell biology. The
functional significance of protein-protein interactions suggests that interactions have likely
evolved to occur only between selected protein partners. The highly specific nature of protein-
protein interaction has indeed been demonstrated in vitro and in vivo' in numerous studies.
Recent efforts aiming to profile protein-protein interactions comprehensively in selected
organisms have further provided a picture of such specificity on a global scale2,3,4.
One key question to protein biochemists is how protein-protein interaction specificity is
achieved. Assays studying protein-protein interactions in isolation of their native environment,
especially those done using purified proteins, have clearly demonstrated that interaction
specificity can be encoded within proteins themselves 5'6. This further suggests that protein-
protein interaction specificity can be encoded at the primary sequence level, as protein primary
sequence determines three-dimensional structure7, which in turns determines interaction
properties in solution.
It is perhaps not surprising that proteins with very different sequences can fold into different
structures and have distinct interaction properties. However, many recent studies have revealed
that proteins (or protein domains/motifs) highly similar in sequence and/or structure can possess
very different interaction specificities as well. These observations suggest that diverse interaction
specificity can be evolved from a common protein sequence family/structural fold. A major
implication is that interaction networks can be evolved with increasing complexity without the
need to reinvent all important protein components from scratch. Examples include modular
domains such as the PDZ5'8'9'10, Src homology 2 (SH2) 1"' and the Src homology 3 (SH3) 13,14
families that are present in many cell signaling proteins, the coiled-coil motifs of different bZIP
transcription factors6, the Bcl-2 proteins involved in apoptosis 15, and cell-adhesion molecules
16such as the Drosophila protein Dscam1 . Dscam represents a particularly interesting case from an
evolutionary perspective. Dscam consists of 10 immunoglobulin-like domains, three of which
are variable and play important roles in homodimerization. Each of these 3 variable domains is
encoded by an exon block, and mutually exclusive splicing at each block gives rise to more than
10,000 distinct isoforms. It was shown that each variable domain is largely specific for
interaction with itself, and their combined action results in high hemophilic binding specificity
for the full-length Dscam16, a key property for neurons to distinguish self from non-self (self-
avoidance) in development. Evolutionary analysis suggested that each exon block was evolved
by exon duplication followed by sequence divergence17 , illustrating how selective pressure
exerted by the desire to maintain self-avoidance can help shape the remarkable homo-specificity
for the Dscam family.
Interestingly, solved structures of proteins with similar sequences but distinct interaction
specificities have revealed that often the same binding interface is utilized, and specificity can be
attributed to local differences in structures18,19,20,21, 22,23, 24,25,26 (Fig 1.1). One mechanism by which
natural proteins can change their interaction properties but still preserve a common protein fold
is to adopt different conformations for loops linking helices/strands that define the basic scaffold.
A good example is the SH2 family, which interacts with peptides that contain a phosphorylated
1112
tyrosine (pTyr)"' . Specificity of SH2 domains interacting with different pTyr peptides is
crucial for specificity in transmitting signals from protein tyrosine kinases to their downstream
pathways. Three main specificity classes of SH2 domains have been discovered that recognize
peptides with different sequence signatures C-terminal to pTyr, including ones with an Asn at the
second residue C-terminal to pTyr (P+2), ones with a hydrophobic residue at P+3, and ones with
a hydrophobic residue at P+4. Loops flanking the binding interface for SH2 domains confer
selectivity toward these 3 types of peptides by opening or blocking binding pockets for the P+2,
P+3 or P+4 residues19,20 The SH3 family also utilizes different loop conformations at the
19binding interface to provide specificity toward different peptides that are rich in prolines.
Antibodies provide another classic example of using loops to confer different binding
properties2 3 , sharing a common immunoglobulin scaffold but using variation in 6 surface loops,
the complementarity-determining regions (CDR), to achieve exquisite specificities for their
target antigens.
Although larger changes in local conformations such as loops present a convenient way to
change interaction properties, examples of more subtle sequence/structural features providing
specificity abound in nature as well. One such example is the interaction between colicins
endonuclease (DNases) and immunity (Im) proteins. Colicins are stress-induced E. coli
bacteriocins that target other E. coli cells. Toxicity of colicins against their own producing cells
can be neutralized by binding to their cognate Im proteins, so high interaction specificity is
critical. A crystal structure of a non-cognate complex between E9 DNase and Im2 was solved in
a recent study and comparison was made to the structure of the cognate complex between E9
DNase and Im924 . It was observed that backbone and sidechain packing at the core of the two
interfaces was highly similar. However, the presence of unfavorable polar/charged residue burial
and sub-optimal hydrogen bonding patterns weakened interaction significantly for the non-
cognate complex. For bZIP coiled coils, structural and mutational analysis have revealed
presence of specificity features described by particular patterns of hydrophobic packing,
hydrogen bonding, and electrostatic interactions between different sidechain pairs25 . Interaction
can be encoded through combination of these features, without any significant change in
backbone structure. For the SH2 and SH3 domains discussed in the previous paragraph, it has
also been shown that structural features similar to the ones described above are important to
further fine-tune the specificity obtained from loops'2 14 19
Figure 1-1 Examples of protein-protein interactions that achieve specificity using a
common structural fold.
A representative complex structure was shown for each class of interactions: (A) Complex
between a SH3 domain from the Abl tyrosine kinase and a proline-rich peptide. (PDB ID:
lABO)156 . (B) Complex between a SH2 domain from the SAP protein and a phosphotyrosine
peptide (PDB ID: lD4W)'57 . (C) Complex between an Erbin PDZ domain and the C-terminal tail
of the ErbB2 receptor (PDB ID: 1MFG)'5 8 . (D) Complex between the bZIP coiled coil motifs of
FOS and JUN (PDB ID: lFOS) 5 9. (E) Complex between the anti-apoptotic Bcl-2 protein Mcl-i
and the BH3-only peptide Bim (PDB ID: 2PQK)16 0 . (F) Complex of a homodimer formed by the
N-terminal domain of a particular Dscam isoform16 1
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Examining different strategies used by nature to achieve interaction specificity offers the
exciting possibility that one can mimic or devise new strategies to design interaction specificity.
In fact, many attempts have been made to change interaction specificity for the different protein
systems described above by altering loops or simply introducing one or a few amino acid
mutations at their binding interfaces 27,2 8,29 ,30 . Given the importance of protein-protein interaction,
the ability to design protein-protein interaction specificity could find many applications in the
study of cell biology 1. Proteins have been redesigned to create dominant negatives/potential
therapeutics specific for the target32,33,34, to generate obligate heterodimers35 ,3 6, to test the
functional significance of the many different interactions of an original protein 37 38, and to create
novel interactions to rewire cell signaling in synthetic biology applications 9 '40 . In addition to
these applications, evaluating the success/failure of designs can help examine and advance our
understanding of how protein primary sequence influences interaction specificity.
Traditionally, researchers have attempted design using rather general knowledge obtained
from structural/mutational analysis of protein-protein interactions. For example, the importance
of hydrogen bonding, favorable electrostatics, and shape complementarity are well known41 .
Nonetheless, this approach often fails to capture the complexity/subtlety of how sequence
influences interaction specificity. Experimental alanine scanning 42,43 and hydrophile scanning44
have also been used to generate proteins/peptides with novel interaction specificities, but the
chemical diversity accessible by such approaches is rather limited.
Recent technologies, both computational and experimental, have helped revolutionize the
field of protein design. Below I first introduce the concept of computational protein design and
its application to designing protein-protein interaction specificity. I then survey the field of
experimental library screening, with particular focus on how its combination with computational
protein design could become a powerful approach moving forward.
Computational protein design
The idea behind computational protein design stems from the principle that because protein
primary sequence determines protein function in solution, one should be able to develop a
quantitative understanding of the relation between sequence and function 5' 46' 47. In the context of
protein-protein interaction8 '49 , function refers to the free energy change (ALG) of the protein
interacting with its partner. If such a relation could be computed, one could perform
computational instead of experimental searches through the vast sequence space in order to
identify sequences with the desired properties.
Scoring function
Different types of scoring models have been developed to compute energy from sequence.
Among them, physics based structural modeling is the most general, as it aims to address the
question using basic physical principles50 . In this approach, the structure of a protein/protein
complex is first predicted from sequence, and an energy score is computed from the structure.
The complexity of protein molecules largely prevents their description directly by quantum
mechanics except in special instances5 1 ,52 , and the energy is usually evaluated as a combination
of molecular mechanics terms such as van der Waals and Coulombic electrostatics . Solvation
of the protein is often approximated by a polar and a non-polar component to avoid the
computationally expensive cost of treating water molecules explicitly54 . The polar component
addresses (1) the screening of electrostatic interactions within the protein by the surrounding
solvent and (2) the energetic cost of burying and thus desolvating a charged or polar amino acid
side chain in a folded protein. The polar component is often computed using a continuum
electrostatics model"' 56'57. The non-polar component attempts to describe the hydrophobic effect
and can be approximated using terms that depend on solvent accessible surface area, or other
methodss8,9,60,61,62 . Not surprisingly, the necessity to include different approximations for
physics based models affects their accuracies. This will be discussed in more detail later.
In contrast to physics-based models, statistical potentials aim to estimate energies using
statistics derived from the PDB. These potentials usually approximate the energy as the sum of
terms describing interactions between two residues 63 or two atoms64' 65 contacting each other in
the structure being evaluated, although attempts to capture higher order interactions have been
reported 66'67. The score for a particular residue-residue or atom-atom interaction is based on the
observed number of such contacts from the PDB, corrected for by the expected number of
random encounters for the same residue or atom pair. A contact can be defined simply on a
distance basis64'65, but more sophisticated potentials take into account other information such as
orientation 68,69 or the environment of the contact as well7 0 . One advantage of statistical
potentials is their speed compared to physics based structural models. In addition, it is known
that current physics based structural models do not always accurately describe the geometry of
interactions between different residues or atoms observed from the PDB. Examples include
certain packing preferences among hydrophobic sidechains7 1 and the angle distribution of
hydrogen bonds 72 . On the other hand, statistical potentials have their own big approximations in
converting observed statistics into energies73, and by no means present a more physically
meaningful formulation than physics based models. Statistical potential have been used in
multiple prediction and design problems7 4 including protein-protein interactions75' 76. Potentials
that include terms from both physics based models and statistical potentials have also been
develop (e.g. Rosetta77) and have had great success in many applications.
Design objectives
After choosing the scoring function, one must define the objective(s) for which a designed
sequence would be optimized. One could optimize a protein-protein interaction by minimizing
the interaction energy (AAG), calculated by subtracting the energy of each protein partner
modeled in its unbound forms from the energy of the modeled complex. Approximations such as
a rigid-body docking or even less formal definitions are sometimes employed, due to difficulty
in modeling the unbound reference states78' 79.
For designing protein-protein interaction specificity, one often needs to consider interactions
with one or more undesired proteins, in addition to that with the target. Determining beforehand
how specific the designed protein should be when predicted computationally (i.e. the predicted
energy gap between binding the target and binding the undesired proteins) is not straightforward.
As scoring functions are not always accurate, it is tempting to pick designed proteins predicted to
be highly specific as a larger predicted specificity gap is likely more tolerant of errors in
prediction. However, it is known that trade-offs can exist between affinity toward the target and
specificity against the undesired proteins0'81'82. Focusing only on widening the specificity gap
can therefore create designed proteins that are specific but bind the target weakly. Depending on
the application, it can be beneficial to explore a range of different designs with different trade-
offs in affinity and specificity. More specific examples of this will be presented later.
Search in structure and sequence space
Guided by a scoring function and the objectives, the next critical component in design is to
search for sequences with desired properties among an immense and combinatorial space.
Because evaluating a sequence requires the determination of its optimal structure, the search
needs to be performed in both structure and sequence space. For redesigning protein-protein
interactions, if a crystal structure of the protein complex being redesigned is available, it is often
assumed that the backbone of the redesigned complex will not be perturbed by sequence. Such a
fixed-backbone design approach therefore considers only structural degrees of freedoms for the
side chains. The repacking of side-chain conformations can be further simplified by sampling
from a pre-defined rotamer library8 3. Energy minimization can be used to relieve serious steric
clashes that stem from artifacts in discretizing the side-chain conformations.
Although success has been reported for many design applications using a fixed-backbone
approach, it is clear that even a small number of mutations can sometimes introduce significant
variation in backbone geometry84' 85. Designing on a fixed backbone therefore risks the
elimination of viable sequences that could be otherwise accommodated if backbone flexibility
were treated. This is especially relevant for designing specificity, as interaction modeled with an
off-target on a fixed backbone might not represent its lowest energy conformation. Different
approaches have been proposed to introduce backbone flexibility on a local or global
scaless87 ,88 ,89 ,90 ,91,92 . For example, Fu et al. demonstrated that designing on an ensemble of
helices generated from normal mode analysis for binding the protein Bcl-xL produced binders
with more diversified sequences 9 . Smith et al. found that the incorporation of "backrub
sampling", a sampling method inspired by examining small, local structural variations within the
PDB, significantly improved the performance in predicting binding profiles for different PDZ
domains91.
Both deterministic algorithms (e.g. dead end elimination (DEE), A* and integer linear
programming) or stochastic ones (e.g. Monte Carlo (MC) and genetic algorithms) can be used for
optimization in the structure/sequence space93 94 95 96 97 ,98. Deterministic algorithms are powerful
but can present problems when the scoring function contains a non-pairwise decomposable term
such as continuum electrostatics, or when backbone flexibility is treated explicitly. Different
efforts have been presented to partially overcome such difficulties99' 100' 101. Although stochastic
algorithms might not always be able to converge on the optimal solution, they can be more
robust in accommodating different formulations/objectives and might be the only viable option
when the search space is too large for deterministic methods98. Different heuristics have been
presented to manage the search problem. For example, search using a fast but less accurate
pairwise decomposable scoring function can be performed first to narrow down the sequence
space, and a more sophisticated scoring function can then be used for evaluation 0 2 . Recently,
Grigoryan et al. proposed a novel framework, CLASSY, in which a technique called cluster
expansion is first used to approximate a structured-based scoring function by a linear sequence-
based scoring function 03; the optimization algorithm integer linear programming (ILP) can then
be run for optimization in sequence space only 0 . In addition to dramatically reducing the time
spent on evaluating a sequence during the optimization, the ILP formulation allows the
incorporation of multiple linear constraints, making it ideal for exploring different trade-offs in a
multi-specificity design problem.
Application to designing protein-protein interaction specificity
Successful examples of the computational protein design of interaction specificity have been
reported for a number of different proteins. Many of these consisted of redesigning sequences for
two interaction partners to create obligate heterodimers or orthogonal protein
81,102,104,105,106interfacess . Among one of the first examples in explicitly designing for specificity,
Havranek et al. designed homo and hetero-specific dimeric coiled coils with novel specificity
determinants not present in native coiled-coil sequences107. Bolon et al. redesigned the SspB
homodimer into an obligate heterodimer, and demonstrated experimentally the importance of
explicit negative design in this example"1. Green et al. 0 2 , Kortemme et al.104 and Sammond et
al.105 also explored the redesign of native protein interfaces to create designed interfaces that are
orthogonal. Potapov et al. presented an interesting approach for such interface redesign by
considering a protein interface to be made up of different modules (sets of interconnected
residues) independent from one another. A module at the interface between TEMI f-lactamase
and its inhibitor protein BLIP was replaced with another module from an unrelated protein
interface. The resulting interface was shown to be orthogonal to the original one and still retained
high affinity'0 6 .
Other studies concentrated on redesigning proteins to selectively bind the desired target over
a number of undesired off-targets9. Yosef et al. reported the redesign of calmodulin to
specifically target one peptide sequence over another. Interestingly, only positive design for
binding the target was considered, yet the design was verified experimentally to be -300 fold
specific' 9. Continuing the previous discussion on objectives for protein design, it was suggested
that explicit negative design might not be necessary in this case when the target and the off-target
are significantly different from one another '. In a landmark example of explicitly considering
negative design against off-targets for inhibitor design, Grigoryan et al. designed specific
inhibitor peptide against all 20 human bZIP families, and subsequent experimental testing
verified that some of the designed peptides indeed showed the desired global specificity80.
Challenges for computational protein design
Significant challenges remain for computational protein design of interaction specificity.
These challenges are present in all aspects of protein design. One fundamental limitation is that
predicting protein-protein interaction specificity reliably is still a difficult task. Possible sources
of deficiencies in physics based models have been suggested in different studies, in addition to
the ones described before regarding hydrophobic sidechain packing preferences and hydrogen
bonding (see the section on scoring functions). Favorable electrostatics at the protein interface
might not be properly balanced with the energy cost of interfacial charge burial'10 . Insufficient
structural sampling could produce artificial steric clashes or fail to identify the optimal
conformation"' 11 . These issues can be rather subtle and difficult to improve upon. Various
modeling suites that adjust relative weights of different physics based scoring terms or use
different approaches for structural sampling have been developed 92,1 12,1 3,114 , partly guided and
tested by available mutational free energy change data. Predictions made from these models
correlated with the mutational data to a certain extent, but the agreements were not impressive
and their performances on protein-protein interaction specificity could be further compromised.
As described before, statistical potentials can possibly address some of the deficiencies in
physics based models. However, they present their own deficiencies and have not been
demonstrated to be able to make reliable on a global scale either.
Of course the imperfectness of scoring functions should not prevent attempts at computational
protein design. In design, researchers enjoy the advantage of testing only sequences predicted to
be optimal, allowing a greater tolerance of prediction error. Researchers can also focus on testing
designs generated with strategies that they have higher confidence in. For example, Lippow et al.
successfully improved the affinities for different antibodies by mainly optimizing energy
contributions from electrostatics"1 . Sammond et al. also presented a series of filters based on
general knowledge of protein-protein interactions that the predicted affinity-enhancing mutations
need to pass before being tested"'7 . However, one could imagine that as the design problem
becomes more and more challenging, e.g. a specificity design problem involving multiple off-
targets, demands on the accuracy of the scoring function will increase as well, possibly offsetting
other advantages offered by computational protein design.
One potential strategy to address deficiencies in physics or statistical based structural
modeling is to supplement them with models derived from other sources such as experimental
data'1"8" 19 . This was illustrated in the study by Grigoryan et al. on comparing performances of
different models for predicting interaction specificity among -50 human bZIP coiled coils 8 .
Two models, one trained by support vector machine (SVM) on independent sequence and
experimental data for coiled-coil interactions 120 , and another parameterized directly using
experimentally measured coupling energies for bZIP coiled coils' 2 ' showed significantly better
performances than pure structural models on predicting specificity. One caveat for
experimentally derived models is that information not present in the experimental dataset from
which the models are derived cannot be learned. Hybrid models that combine physics based
structural models with the experimentally derived ones have been developed to address this.
These hybrid models were in fact used in the study of Grigoryan et al., as described above, to
design globally specific inhibitor peptide against 20 human bZIP family proteins80 . The accuracy
offered by the experimentally derived models is likely crucial for the success of the designs. It is
tempting to generalize such approaches to other interaction specificity design applications as
well. However, this approach requires the presence of a large amount of experimental data
relevant to the protein being studied, which is often not available for many proteins of interest.
Information encoded within the evolutionary history can also be utilized to provide insight on
protein-protein interaction specificity 122,123, but such methods often required ample sequencing
information and at least some knowledge of interaction patterns across different species for the
proteins of interest.
Experimental library screening
Like computational protein design, experimental library screening/selection is motivated by
124the desire to search among a large number of sequences for ones with the desired properties
Below I first briefly review several key experimental aspects of library screening/selection,
including different techniques for generating sequence diversity and different screening/selection
platforms. I then focus on the emerging trend of how library screening can be combined with
computational protein design to facilitate the discovery of desired sequences.
Generating sequence diversity
The first task in performing a library screen is to generate an ensemble of sequences
experimentally. This is typically performed at the DNA level, with diversity translated to protein
sequences at a later stage. Genes with randomization at selected positions can be made by PCR-
based assembly procedures using partially randomized oligoneucleotides containing degenerate
codons125 It is possible to encode randomness at a position by using a mixture of multiple non-
randomized oligonucletides126 or by utilizing trinucleotide synthesis 127 as well. However, issues
such as how distant the randomized positions are from each other in sequence, how many
randomized positions are placed closely together, and how much diversity needs to be introduced
at these positions affect whether the PCR assembly procedure can be performed cost-effectively.
Alternatively, diversity can be generated by recombining fragments from different native or
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synthetic genes, mimicking the process of homologous recombination' . It should be noted that
common methods for introducing diversity often place constraints on the types of sequences that
can be generated. For example, randomization at selected positions dictates that the sequences
will be combinatorial with respect to diversity at these positions. Recombination among gene
fragments, on the other hand, will result in combinatorial sequences with respect to the fragments.
Instead of introducing randomization at defined positions/fragments, mutations can be
introduced randomly across the whole protein (or a selected sub-region) using error-prone PCR
or other methods 29" 3 .
Note that different randomization strategies can be combined together. One good example is
the process leading to diversification of human antibodies13 1 . The variable region of each class of
antibody chain is assembled from different types of gene segments (the V, D, and J segment) in a
site-directed recombination event known as V-D-J joining. The presence of different variants for
each type of gene segment leads to a combinatorial diversity estimated to be bigger than 105.
Mechanisms such as somatic hypermutation and gene conversion are employed to further
increase diversity and generate antibodies of sufficient affinities for their targets (affinity
maturation). This process of generating a preliminary pool of sequence diversity from which
selected sequences are further optimized can be mimicked in vitro as well. For example,
randomization can first be introduced in a guided manner by recombining different native or
synthetic gene fragments (analogous to V-D-J joining) or by mutating selected positions in a
combinatorial manner. Promising sequences can be identified and techniques like error-prone
PCR (analogous to somatic hypermutation) can be performed to further optimize their properties.
Screening/selection platform
Next an appropriate screening/selection platform needs to be chosen. This depends on a
number of different factors, including the size of the DNA library and the desired activity to be
screened or selected. Different molecular display technologies 3 2 such as phage display133,
bacterial display1 34, yeast display 3 5 , mRNA display' 36 and ribosome display' 37 have been widely
used to screen for desired protein-protein interactions, although other platforms such as yeast
two-hybrid have been considered as well. Cell free display methods (mRNA, ribosome) and
phage display allow the handling of much larger library sizes (> 1014) than those affordable by
cell-based display methods (109-101o for bacterial display and 107-109 for yeast display).
However, for bacterial and yeast display, florescence activated cell sorting (FACS) can be used
to sort cells displaying the desired sequences in solution. This bypasses the need to first
immobilize and then elute the desired clones from a surface, which is often required in cell-free
display technologies. This is advantageous when selecting for protein-protein interaction
specificity, as conditions for competition or negative selection can be more easily tuned by
simply varying the concentration of target and off-targets.
Combining computational protein design and experimental library screening
Compared to computational protein design, experiments are directly used to evaluate a
sequence in library screening, largely removing the worry that the designed sequences might not
behave as predicted. However, relative computational protein design, library screening can only
be performed for a much more limited number of sequences. This raises concerns as to whether
the combinatorial sequence space can be adequately sampled, because mutations picked
randomly are rarely beneficial for the desired trait. Following the thinking behind computational
protein design, it is therefore tempting to combine the advantages of these two methods. Instead
of computationally designing a few sequences, one can computationally design a library.
Sequences in the library will not be chosen randomly, but are instead selected on the basis of
computational structural modeling. Although the computational models might not be perfect, as
described previously, they could nevertheless help bias the experimental search to a more
productive sequence space.
The idea of combining computational protein design and experimental library screening has
been explored by several different groups 18-141. Computationally designing a library presents
distinct challenges from designing a selected number of sequences. One major difference is that
practical aspects of the chosen experimental strategies need to be given due consideration during
the computational design phase. As described before, for most experimental library construction
protocols, the diversity of library sequences will be combinatorial with respect to positions or
gene fragments. The screening platform also places a limit on the number of sequences that can
be tested. Another important difference is that the library design objective is no longer obvious;
one must decide whether the designed library should cover a particular set of sequences, whether
the predicted behaviors for all library sequences should be evaluated, or if diversity among
library sequences is most important. There may be multiple objectives that one aims to
consider/optimize, and different trade-offs could exist among these. For example, the desire to
create a library at lower cost could mean more restrictions on the type of sequences that could be
included. Aiming to sample a larger sequence space through the library could imply a less than
ideal coverage for the designed sequences overall.
Below I review the different approaches used to computationally design a library and their
applications for different design problems. Although few studies focused on the question of
designing protein-protein interaction specificity, the general concepts should have broad
relevance.
Designing a library with selected positions randomized
Several approaches have been suggested for designing a protein library with selected
positions randomized. In the first approach, a library "score" is first defined, and the library is
designed to optimize this score. Treynor et al. defined the score to be the arithmetic average of
the energies calculated by structural models of all sequences in the library4 . Optimization of
this library energy is analogous to optimizing the energy of a single sequence, with the search
being performed in the space of degenerate codons (could be viewed as sets of amino acids)
instead of amino acids. Libraries of green fluorescent protein (GFP) variants were designed
accordingly to enrich sequences compatible with the structural fold of GFP. It was observed that
these libraries contained a greater fraction of proteins that fluoresced, as well as a greater
diversity of colors, compared to an error-prone PCR library. In a separate computational study,
Parker et al. also defined library quality to be the averaged energies of all library sequences, but
proposed to considered as well another objective that represented the novelty of the library
sequences (e.g. when compared to a multiple sequence alignment of homologous native
proteins) 48 . Optimization was performed using integer programming in the space of degenerate
codons that included consideration of library size. Parker et al. further demonstrated for a few
protein systems the trade-off between quality and novelty as defined above computationally. As
described before, the concept of trade-offs among different library design considerations is an
important one and worth contemplating when weighing the relative importance of different
aspects for library design.
In the second approach, computational protein design is first performed to obtain an ensemble
of sequences. An amino-acid profile (i.e. the frequency of different amino acids at each designed
position) is derived from these sequences, and the library is designed with the aim to match the
diversity observed in the profile. One caveat is that the library obtained accordingly may not
reflect the original ensemble of designed sequences. Hayes et al. used this approach to design a
library of TEM p-lactamase variants to screen for clones with improved resistance toward the
antibiotic cefotaxime 26. Randomization was introduced to the active site, and compatibility with
the protein fold (i.e. the crystal structure of TEM p-lactamase) was assessed in designing the
sequence ensemble. Variants with a 1,280 fold increase in resistance were identified out of a
-200,000 member library. Guntas et al. also used this approach to design a library of variants of
the ubiquitin ligase E6AP that binds to the NEDD8-conjugating enzyme Ubc 12, a nonnatural
partner, and obtained multiple tight binders (Kd < 100 nM) from the screen144 . Degenerate
codons were selected at each position by considering their efficiencies in representing the amino-
acid diversity profile and the library size. One interesting observation from this work is that
equally good performances were obtained for the designed library enriched in predicted binders
and that enriched simply in well-folded sequences. Both libraries performed better than a random
library.
In the third approach, an amino acid diversity profile is derived from a probabilistic
framework rather than from an ensemble of designed sequences. Voigt et al. applied mean-field
theory to capture the structural tolerance of each designed position'38 . The study aimed to use the
metric as a guide in selecting positions for randomization, and good agreement was observed
with prior experimental directed evolution studies of subtilisin E and T4 lysozyme. Saven and
coworkers also proposed using a statistical theory for the design of combinatorial libraries149 150.
Designing a library made by combining different gene fragments
One challenge in making a library generated by in vitro recombination among homologous
native or synthetic genes is how to select the cross-over points. Voigt et al. presented SCHEMA,
an algorithm to help address this issue139 . Points for cross-over were chosen so as to minimize
disruption of important residue-reside interactions as observed in the crystal structure. The
argument is that hybrid proteins generated this way are more likely to be folded and functional.
Correlation between cross-over points predicted from SCHEMA and prior in vitro recombination
experiments was observed, and SCHEMA was subsequently applied to a series of different
design problems 5
One advantage for making a library by combining gene fragments is that correlations among
residues within the same fragment can be preserved. This is in contrast to designed libraries
combinatorial in positions. Although correlation between different designed positions could still
play a role in this type of library by deciding what pair of degenerate codons (or sets of amino
acids) to choose at two separate positions, no coupling between positions is enforced for the
library sequences. As an example of recombining synthetic gene fragments obtained from
computational protein design (as opposed to fragments derived from native genes as performed
by Voigt et al.), Lippow et al. redesigned a galactose oxidase enzyme to process glucose
instead1 45. An ensemble of> 2,000 sequences was first designed computationally. The 12
designed positions were then grouped into 4 assembly regions guided by proximity in sequence.
Each region was then encoded by a mixture of synthetic oligonucleotides such that correlations
between different positions in each region were preserved. The library was assembled from
these fragments. Using this approach, Lippow et al. successfully identified a variant with 400-
fold improvement in activity toward glucose from a 10,000 member library.
Improving computational designs by library screening
One other approach for combining computational protein design and experimental library
screening is to use library screening to further improve existing designs. Although computational
prediction can be used to guide library design, any prediction model not entirely accurate will
generate some bias, meaning that some of the important sequence space will not be sampled,
even by a large library. This is especially relevant for difficult prediction/design problems. In this
case, a more random/less guided strategy could prove beneficial in identifying important
sequence features that would be missed by the model. The approach is demonstrated by
Khersonsky et al. for optimizing the catalytic activity of the in silico designed Kemp eliminase.
Error-prone PCR, gene shuffling and site directed randomization were all employed to generate
diverse library sequences derived from the initial computationally designed sequence. Mutants
with improvement of > 400 fold in catalytic activity were identified from the screen/selection.
One observation from the studies described above is that the metric used for selecting
sequences to be included into the library could be different from the real objective. As described
before, Hayes et al. 126 , Treynor et al.140 and Guntas et al. 144 all designed library sequences to be
compatible with a structural fold but screened the libraries for function (improved enzymatic
activity toward an antibiotic, different photophysical properties, and protein-protein interaction,
respectively). Although a well folded sequence is likely a necessary but not sufficient criterion
for the presence of different functions, its prediction could be much easier and may in fact
represent a more efficient use of the computational prediction model. This could have general
implications for difficult design goals such as protein-protein interaction specificity.
Contributions of this thesis in designing protein interaction specificity
One of the major challenges for computational protein design is that current structural models
that describe the relationship between sequence and structure (or function) are not always
reliable. Above, I summarized and discussed two approaches to address this based on prior
studies. The first approach aims to supplement structural models with more restricted but
possibly more accurate models derived from experimental data. The second approach utilizes the
ability of experimental library screening to survey a more diverse collection of designed
sequences, to compensate for the deficiencies of the prediction models.
In this thesis I first describe the design of an inhibitor peptide that binds to the viral bZIP
protein BZLF1 (Chapter 2). Specificity against design self-interaction was important for this
study. The protein family being studied represents a case for which semi-accurate scoring
functions derived from the first approach were available, and successful inhibitor peptides were
designed accordingly. In Chapter 3, following the rationale behind the second approach, I present
a novel framework that can be used to design libraries to be screened for protein-protein
interaction specificity. I applied the framework to the identification of anti-apoptotic Bcl-2
protein variants with novel interaction specificities toward different BH3 peptides. Designed
libraries were subjected to screening, and clones with the desired binding specificity were
obtained. In Chapter 4, I focus on the question of BH3 sequence determinants of specificity
against different anti-apoptotic Bcl-2 proteins. The study focuses on the application of a purely
experimental scoring model derived from SPOT arrays to the prediction and design problem. I
conclude with a discussion of how the two approaches can be combined together to advance our
understanding and our ability to design novel protein-protein interaction specificity.
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Introduction
The basic-region leucine-zipper (bZIP) transcription factors are a large class of proteins
conserved in eukaryotes and several viruses that regulate a wide range of biological processes.
The structure of bZIP-DNA complexes is very simple: a helical and positively charged DNA-
binding region is contiguous with a coiled coil that mediates protein homo- or hetero-
dimerization.1 The bZIP coiled-coil helices wrap around one another in a parallel orientation with
"knobs-into-holes" side-chain packing geometry, and a 7-amino-acid heptad repeat characterizes
the structure, in which each residue can be assigned a register position labeled a through g (Fig.
2.1). High-affinity binding of bZIP transcription factors to DNA requires protein dimerization.
Given the many important biological roles of the bZIPs, molecules that selectively disrupt
bZIP-DNA interactions could be valuable reagents and even potential therapeutics. Several
strategies have been reported for identifying inhibitors. Small molecules have been discovered
via high-throughput screening,2, 3 and peptides that bind to the coiled-coil regions of the bZIPs
and disrupt dimer formation have been selected from targeted combinatorial libraries. 4,5,6 A
particularly effective strategy for blocking bZIP-DNA interactions was developed by Vinson and
co-workers, who created a series of dominant-negative peptide inhibitors by replacing the basic
regions of certain bZIP proteins with a sequence enriched in negatively charged residues (the
"acidic extension"), giving so-called A-ZIPs. 7'' 9' 10 The A-ZIPs bind tightly and selectively to
bZIPs and have been used to study the effects of inhibiting dimerization and hence DNA binding
in both cell culture and animal models.' 1' 12
Current understanding of bZIP coiled-coil interactions has also enabled the computational
design of synthetic peptides to block bZIP dimerization. Significant effort has been dedicated to
elucidating sequence determinants governing the interactions of bZIP coiled coils, and to
developing predictive computational models that capture these. Several types of residue-pair
interactions that are important for specificity have been characterized in detail over the past 20
years, and models derived from physics-based calculations, machine learning, and
experimentally measured coupling energies have been developed to explain and predict bZIP
coiled-coil interactions. 4' 13, 14, 15, 16, 17 Using such binding models, Grigoryan et al. recently
designed a series of peptides that bind to targets in 19 out of 20 human bZIP families.' 8
An interesting issue in the study of bZIP interactions is specificity. Given the similarities
among sequences, and the many bZIPs in most eukaryotes, a large number of homo- and
heterodimers can potentially form. Interactions among human bZIPs have been shown to be
highly selective when assayed in vitro,19,20 but it can be difficult to achieve specificity in
designed bZIP-like peptides. In particular, peptides engineered to bind to bZIP coiled-coil
regions have been shown to self-associate strongly and also interact with undesired partners. 5' 18
In this work we address considerations of both affinity and anti-homodimer specificity in the
design of peptide inhibitors for a viral bZIP protein, BZLF 1.
BZLF 1 (Zta, ZEBRA, EB 1) is encoded by the Epstein-Barr virus (EBV) and triggers the
virus's latent to lytic switch by functioning as a transcription factor and regulator of DNA
replication.2 1, 22, 23 ,2 4 Infection by EBV has been linked to several human malignancies such as
Hodgkin's disease and Burkitt's lymphoma.2 5 The basic region of BZLF 1 is highly homologous
to that of human bZIPs and is responsible for direct contact with DNA; a coiled-coil region
immediately C-terminal to the basic helix mediates dimerization. However, a recent crystal
structure and other biochemical studies have revealed several unique features of BZLF 1 (Fig.
2. la).26 ,2 7 The coiled-coil region at the dimerization interface is only 4 heptads long, whereas the
coiled-coil regions of human bZIPs typically contain at least 5 heptads. Furthermore, only one of
the four BZLF 1 coiled-coil heptads includes a leucine residue at the d position; this residue
occurs with much higher frequency in human bZIP sequences (hence the name "leucine zipper").
The stability of the BZLF1 homodimer is significantly enhanced by a unique C-terminal (CT)
region that folds back on the coiled coil to form additional contacts; 2 7 the CT region is only
partially observed in the crystal structure. Prior work using peptide arrays showed that BZLF1
constructs corresponding to the coiled coil or the coiled coil plus the CT region homo-associate
in preference to binding any of 33 representative human bZIP proteins. 28
It has been shown that a peptide corresponding to the coiled-coil region of BZLF 1, lacking
the DNA binding residues, inhibits BZLF 1 binding to DNA at high micromolar concentrations. 29
In this work, we sought new peptides that would mimic the coiled-coil interface of the native
structure yet provide more potent inhibition of DNA binding. As a design target, BZLF 1 is both
simpler and more complex than human and viral bZIPs that have been the subjects of previous
computational design studies.i8 ,2 8 It is simpler because of its unique structural features, which
make coiled-coil inhibitors designed to target it unlikely to interact broadly with other bZIP
proteins. However, it is more complex because the CT region and unusually tight helix packing
make the interface unlike the dimerization domains of better-understood bZIPs.26 Here we
explore the extent to which previously applied design strategies can be used successfully in the
context of BZLF 1. Throughout our analyses, we explicitly addressed two design criteria: affinity
for BZLF1 and design self-association, which is an undesirable trait for an inhibitor. The best
inhibitor incorporated both elements and included modifications of BZLF 1 in both the coiled-
coil and DNA-binding regions. As assessed using DNA-binding gel-shift assays, this designed
peptide was much more potent than one corresponding to the native dimerization domain.
Results
Computational design of a peptide to bind the N-terminal part of the BZLF1 coiled coil
Our goal was to identify variants of the BZLF 1 dimerization domain that would function as
more effective dominant negative inhibitors of DNA binding. As described in the Introduction,
BZLF 1 possesses several unique features as a bZIP design target. These include the
unconventional, short coiled-coil segment and the CT region. The CT can be divided into the
proximal CT (residues 222 - 231) and the less structured distal CT (residues 232 - 246), as
shown in Fig. lb. We began by re-designing the N-terminal two and a half heptads of the BZLF1
coiled coil (residues 191 - 209, Fig 2.2b), because we anticipated that this segment would
provide the greatest opportunity to improve affinity and heterodimer specificity over the native
sequence. Residues 210 - 221 also form part of the coiled-coil structure, but additionally engage
in non-coiled-coil hydrophobic contacts with the proximal CT as observed in the crystal structure
(Fig. 2.1 a). Thus, in order to maintain this stabilizing interaction, these residues were not
changed in the design.
Both the desired design-target heterodimer and the undesired design homodimer were
modeled as parallel, blunt ended coiled coils. We used the CLASSY protein-design algorithm to
choose residues at 10 sites in the design, optimizing the predicted affinity of the design-target
complex.18 The scoring function used was based on a hybrid model that included both physics-
based and experimentally derived terms and is described further in the Methods. The optimal-
affinity design, which we call BDc (BZLF 1 design against the coiled-coil region, shown in Fig.
2.2c), was predicted to be hetero-specific. In design energy units the predicted stabilities were as
follows: BZLF1 homodimer: -29 kcal/mol, BDec homodimer: -32 kcal/mol, BZLF1/BDec
heterodimer: -44 kcal/mol. Although the score for the design self-interaction was close to that
for native BZLF1 coiled-coil homodimerization, the score for the design-target interaction was
significantly better. Thus, although CLASSY can be used to improve specificity against
undesired states as well as affinity for a target, 8 this was predicted not to be necessary in this
case.
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Figure 2.1 Sequence and structure of the BZLF1 bZIP domain.
(a) Crystal structure of BZLF 1 bound to DNA26 (PDB ID 2C9L, left) compared to human
JUN/FOS bound to DNA54 (PDB ID IFOS, right). The basic region is blue, the coiled coil is
green, and the C-terminal (CT) region is red. At the bottom are sequence alignments for the basic
and coiled-coil regions of BZLF 1 and representative human bZIPs. Leucines at d positions in the
coiled coils are underlined. (b) Scheme of constructs used in this study. The "231" construct
includes the coiled coil (CC) and the proximal C-terminal (CT) region; the "245" construct
includes the coiled coil (CC) and the full-length C-terminal (CT) region.
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Figure 2.2 Designed inhibitors.
(a) Structural models representing two types of design-BZLF 1 complexes tested in this work. At
left, the "231" constructs, and at right, the "245" constructs. "X" is a placeholder for the name of
a design, e.g. BD. Color is as in Fig. l a except that the designed region is shown in orange. The
dashed boxes in the "245" complex indicate that part of the distal CT (237-245) is not resolved
in the crystal structure. (b) Helical wheel diagram for the BZLF1 homodimer. (c-e) Helical wheel
diagrams for the designs. On the left are design-target heterodimers and on the right are design
homodimers. Design residues are highlighted in bold and with a grey background. Potential
electrostatic interactions are indicated in blue if attractive and red if repulsive. (c) Design BDee,
(d) Design BDIED, (e) Design BDEEI. In all helical wheel diagrams, only residues from b position
191 (Ala) tof position 209 (Ser) are shown (this region is orange in Fig. 2.2a), with the helix
proceeding from N-to-C terminus into the page. Diagrams generated using DrawCoil 1.0
(http://www.gexvorggrigoryan.com/drawcoil/).
(a)
The BDec solution populated most a and d positions (coiled-coil "core" positions) with Ile
and Leu respectively, which are very common in conventional bZIP sequences (Fig. 2.2c). A
single d-position Glu residue at the extreme N terminus of the coiled coil is uncharacteristic of
bZIP sequences, but was predicted to interact favorably with an e-position Lys on BZLF 1. The
five designed e and g positions (coiled-coil "edge" positions) were all populated with glutamate
for improved electrostatic interactions with the target, where three residues in this region are
positively charged. Interestingly, predicted charged interactions involved both edge-to-edge (e.g.
g to e ') and core-to-edge (d to e') residues in the BZLF 1 target, as was previously observed for
anti-human bZIP designs.!8 Although core sites occupied by Ile and Leu favor design self-
interaction, the charged residues at e and g are predicted to disfavor it. Charge repulsion is a
commonly observed negative design element in many native and model coiled coils. 30, 3 1, 32, 33
The anti-BZLF 1 peptide was cloned in the context of residues 191- 231 of BZLF 1. This
construct, BDC, includes the entire coiled-coil domain and the proximal CT (Fig. 2.1b, 2.2a,
Table 2.1), potentially retaining native interactions observed in the X-ray structure between the
C-terminal part of the coiled coil and the CT region. Because the residues optimized in the
design calculations are more than 8 A away from residue 1231 in the modeled structure (Fig.
2.2a), the proximal CT excluded from the calculations was not expected to significantly
influence the results. Potential interactions between the designed residues and the distal CT,
which are not evident in the crystal structure but are suggested by prior studies 27 , are addressed
in experiments described below.
We used circular dichroism (CD) spectroscopy to study the interaction properties of BD..
Thermal denaturation experiments showed that the BD homo-oligomer is destabilized
compared to the target homodimer in the same sequence context (BZLF 12, residues 191 to 231);
Tm values were 38 *C vs. 43 'C (Fig. 2.3a and Table 2.1). The hetero-complex between BD" and
BZLF 1" (Tm of 53 'C, Table 2.2) was significantly stabilized compared to the BZLF 1
homodimer. We conclude that the BD design is very hetero-specific, consistent with
expectations based on the design algorithm. The agreement indicates success of the automated
CLASSY approach even on a target with a sequence quite different from the human bZIPs.
Designs with weaker self-association
The BDc design achieved hetero-specificity mostly by improving design-target affinity
compared to the native BZLF 1 complex. We also sought solutions that achieved hetero-
specificity against the same target (the N-terminal part of the BZLF 1 coiled coil) by weakening
design self-interaction. Toward this end, we tested a negative design strategy that placed charged
residues at a core d position and the adjacent e position such that they would create a local
cluster of 4 negative charges in the modeled design coiled-coil homodimer. There are 3 close
inter-chain pair contacts in such a cluster (2 d-e' interactions and one d-d' interaction). We
observed variations of this strategy in design solutions obtained using the CLASSY algorithm
when optimizing affinity for the target under increasingly stringent constraints limiting the
stability of the design homodimer.
We picked two sets of amino-acid changes, (K207E, S208D) and (Y200E, R201E), each
corresponding to the (d, e') negative design strategy described above. We also included one
stabilizing design element present in the BD solution, A204I (substituting Ile for Ala at an a
position), to compensate for a potential loss in stability due to the introduction of charge in the
core. The resulting two designs were cloned, expressed and purified, again in the context of
BZLF1 residues 191 to 231 (2041, 207E, 208D, referred to as BD j, and 200E, 201E, 2041,
referred to as BD", Fig 2.2d-e).
Table 2.1 Sequencesa and melting temperatures (*C)b for BZLF1 and design constructs.
basic/acid coiled coil proximal CT distal CT
191 221 231 245 Tm
bdisgabcdef 0 gabcdefgMqdli|
BZLF1231  Ad QLLQHYREVA8AdiIENDRLRLid it CPSLDVDSII 43
A-BZLF1231  QRAEELARENEELEKEA BENOIdQELLKYREVAAKftSENDRLRLIIN jI CPSLDVDSII 33
B-BZLF1 231  LEIKRYKNRVASRKCR AiftQLLQHYREV WZIl ENDRLRL&i, M CPSLDVDSII 31
BZLF12 45  AitLLQHYREiiiiiENDRLRLI! Qf CPSLDVDSII PRTPDVLHEDLLNF 71
A-BZLF12 45  QRAEELARENEELEKEA NiiOieELLKYREVAEENDRLRLNIf CPSLDVDSII PRTPDVLHEDLLNF 43
B-BZLF1 245  LEIKRYKNRVASRKCR AKFKQLLQHYREVIANA~SENDRLRLtLn i CPSLDVDSII PRTPDVLHEDLLNF 67
BD23 AKIE EIQHLEEEZL ENDRLRLiJU j CPSLDVDSII 38
BD2s AftEIQHLEEgMdL&ENDRLRLl O' CPSLDVDSII PRTPDVLHEDLLNF 40
A-BD 25 QRAEELARENEELEKEA ENgQELLKLEE_ i ENDRLRLi"_, CPSLDVDSII PRTPDVLHEDLLNF 40
BD2J A.ILLQHYRE XZSENDRLRLtkoANM CPSLDVDSII N/Ac
BD24 AKQiLLQHYREVAMSENDRLRLftgP* CPSLDVDSII PRTPDVLHEDLLNF 26
A-BD2 QRAEELARENEELEKEA tiiY5EELLKYRE ENDRLRLtN* CPSLDVDSII PRTPDVLHEDLLNF N/Ac
BD2 1  ARNLLQHEEENglsiiiENDRLRLtiill O CPSLDVDSII N/Ac
a The sequences SHHHHHHGESKEYKKGSGS, or GYHHHHHHGSY (the latter for constructs
with the acidic extension, A-) should be placed at each N terminus to obtain the full sequences of
the recombinant proteins listed in the table. Sites with amino acids different from those of the
native sequence (either introduced in the design or as part of the acidic extension) are underlined.
Different regions of the sequence (basic region/acidic extension, coiled coil, proximal CT and
distal CT) are separated by space. As explained in the text, the acidic extension overlaps the 9 N-
terminal residues of the coiled coil. Coiled-coil heptads are indicated using shading.
b Total protein concentration was 4 1M.
'N/A indicates either lack of cooperative folding or that the observed melting curve indicated the
presence of more than one species.
(*C) for different BZLF1/design hetero-interactions.
Target Design Tma ATmb
BZLF 123 ' BD2 53 12 (43/38)
BD23 N/Ac N/Ac
B-BZLF 1245 BD2 66 12 (67/40)
BD24 N/Ac N/Ac
A-BD2 >80 > 26 (67/40)
A-BZLF1 245  74 19 (67/43)
B-BZLF 1231 A-BZLF 1231 58 26 (31/33)
JUN BD2 41 10 (23/40)
a Total protein concentration was 4 tM.
b ATm was obtained by taking the Tm for the hetero-complex and subtracting from it the average
of the Tm values for each individual species (listed in parentheses for easy comparison, Tm for the
target is shown first, followed by that of the design) when applicable.
c N/A indicates either lack of cooperative folding or that the observed melting curve indicated the
presence of more than one species.
Table 2.2 Melting temperatures
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Figure 2.3 Melting curves for targets, designs and complexes monitored by mean residue
ellipticity at 222 nm.
Four curves are shown in each panel: the target at 4 ptM (open triangles), the design at 4 pM
(open circles), a mixture of the target and the design at 2 gM each (closed squares), and the
numerical average of the individual melting curves for the target and the design (short dashed
lines). The target is BZLF1 23 1 for panels (a) - (c) and B-BZLF1 24 5 for panels (d) - (f), as
described in text, and the designs are: (a) BDcc, (b) BDIE, (c) BDEEI, (d) BD~cC, (e) BDID,245and (f) A-BDcC-
Thermal denaturation experiments monitored by CD showed that both designed peptides,
BD2D and BD 23, had relatively weak helical signals even at very low temperatures (Fig. 2.3b, c),
illustrating the effectiveness of the negative design strategy. We compared the melting curve for
the mixture of each design and BZLF 1231 with the numerical average of the individual melting
curves for each species (Fig. 2.3b, c). The difference between the two curves below -22 'C
reflects interaction between the designed peptides and BZLF 1", and confirms that the designed
peptides bind the target more strongly than they interact with themselves. However, an
interaction is evident only at low temperatures, indicating that the stability of the design-target
complex is lower than the BZLF 1"2 target homodimer. Therefore, these 2 designed peptides
represent a specificity profile distinct from that of BD"; one that achieves greater destabilization
against design self-interaction at the expense of the stability of the design-target interaction.
BDee and BZLF1 form a heterodimer
We modeled all coiled-coil interactions as parallel, symmetric dimers. Although the
oligomerization states of coiled coils can be sensitive to very few amino-acid changes, 34 ,3 5 in
BZLF 1 the presence of the CT region is expected to strongly favor the parallel dimer geometry
observed in the crystal structure for BZLF1. The designed heterodimer also includes an Asn-Asn
interaction at a-a', which has been shown to strongly favor dimers, and multiple charged
residues at the e and g positions that are also more prevalent in dimers.36 Nevertheless, we
performed analytical ultracentrifugation (AUC) experiments to study the interaction between
BD2 and BZLF 1231. Global analysis of sedimentation equilibrium runs performed at multiple
concentrations and rotor speeds showed that the best-fit molecular weight for both BD1 and the
1:1 mixture of BD2 with BZLF 1231 corresponded to that expected for a dimer (representative
data are shown along with the global fit in Fig. 2.4). For BD with BZLF 1231, the fitted
molecular weight was 104% of that expected for the heterodimer, with a fitted RMS of 0.027
fringes. RMS values obtained by fixing an exact dimer or trimer weight were 0.029 or 0.090
fringes, respectively. For BDC, the fitted molecular weight is 102% of that expected for the
homodimer, with a fitted RMS of 0.021 fringes. RMS values obtained by fixing a dimer or a
trimer weight were 0.021 or 0.10 fringes, respectively. The AUC data thus confirm the validity
of modeling these interactions as dimers.
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Figure 2.4 Representative analytical ultracentrifugation data for BD" + BZLF123' (left)
and BD" (right).
The fits shown were obtained with data collected at 2 concentrations and 3 different centrifuge
speeds. At the bottom are the residuals to the fit.
Testing designs in the full-length BZLF1 dimerization domain
The designs described above targeted the BZLF1 coiled coil and were tested in the context of
BZLF 1231. However, inhibitors of protein function must bind to the full-length protein. One
difficulty with designing against the entire BZLF1 dimerization domain (residues 191 - 245) is
that the crystal structure shows only the proximal and part of the distal CT region (up to residue
236), with the remaining part of the distal CT region contributing no electron density.2 6
Nevertheless, the distal CT region (Fig. 2.1b) has been shown to contribute positively to BZLF1
dimer stability despite possibly being less structured.
We tested whether our design procedures, which considered only the structured coiled coil,
could provide molecules that bind the full-length BZLF 1 dimerization domain. For this purpose,
a BZLF 1 construct that included both the DNA binding basic region and the full-length
dimerization domain (termed B-BZLF 124, residues 175-245, Table 2.1) was used instead of
BZLF12 " as the target. The designed mutations in BD"' and BDJ were made in the context of
the full-length BZLF1 dimerization domain without the basic region (residues 191-245) to create
two new design constructs, BD.c. and BDJ" (Fig. 2.2a, Table 2.1); the distal CT was included in
the design constructs to exploit its potentially favorable interaction with the target.
The distal CT dramatically stabilized the BZLF 1 homodimer (compare BZLF 1231 and
BZLF1245 Tm values of 43 'C and 71 'C, respectively), consistent with prior reports.27 In contrast,
self-association of the BDc design was not significantly stabilized by the distal CT (Table 2.1).
When BD2 and B-BZLF 1245 were mixed, there was clear evidence of interaction (Fig. 2.3d,
Table 2.2). However, the hetero-interaction between BD2 s and B-BZLF 124 did not appear to be
stronger than the self-association of the target B-BZLF 12" (Table 2.1, 2.2), which contrasts with
the behavior of the shorter constructs, BD2 and BZLF 1231 (Fig. 2.3a, Table 2.2). Differences in
relative stabilities for the shorter and longer constructs suggest that residues in the design do not
interact as favorably as the native residues with the distal CT.
In contrast to BDc, analysis of BDI" showed that both the design self-interaction and the
design-target interaction were stabilized by the distal CT (compare Fig. 2.3b with Fig. 2.3e). As a
result, BD2" was heterospecific at low temperature. Compared to BD 24, BD2" showed weaker
self-association but also displayed weaker affinity for B-BZLF 1245. Together, the results show
that the effect of the distal CT is not negligible and depends on sequence in the coiled-coil region.
The impact of the distal CT on the specificity profiles for different designs is considered further
in the Discussion.
Specificity of BDee against human bZIPs
Specificity against human bZIP proteins was not addressed explicitly in our design
procedure because we reasoned that the CT region, which is unique to BZLF 1, would likely
stabilize interaction with BZLF 1 but not with human proteins. To assess this, we selected a few
human bZIPs and evaluated their interactions with BDc using CD spectroscopy. To identify
those human bZIP proteins most likely to associate with BDec, we calculated interaction scores
with 36 representative human bZIP coiled coils using the scoring function employed in the
CLASSY algorithm, which has been shown to be useful for evaluating bZIP coiled-coil
associations (Fig. 2.5a).13'1 Interestingly, BDee was predicted to interact more favorably with
BZLF 1 than with any of the human bZIPs, even though the scoring scheme used did not consider
interactions involving the CT region. We chose 5 of the top 10 scoring complexes for
experimental testing, selecting representative proteins that spanned 5 families and included JUN,
the closest predicted competitor. We used constructs for the human proteins that included the
basic region and the coiled coil (Fig. 2.5b-f). Analysis of melting curves for each human bZIP
and each 1:1 mixture with BD. showed that only JUN interacted with BD". The BD"/JUN
complex, however, was significantly weaker than that between BD" and B-BZLF 1"" (Tm values
of 41 'C vs. 66'C, Table 2.2). Thus, BDcc is not a promiscuous design and binds preferentially to
its target, BZLF 1.
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Figure 2.5 Specificity of design against human bZIPs
(a) Predicted scores for BDee interacting with BZLF1 or human bZIP peptides. (b-f) Melting
curves for selected human bZIP peptides, BD24 or 1:1 mixtures of the two, monitored by mean
residue ellipticity at 222 nm. Four curves are shown in each panel: the human bZIP at 4gM (open
triangles), BDCC at 4 gM (open circles), a mixture of the human protein and BD2C at 2gM each
(closed squares), and the numerical average of the individual melting curves for the human bZIP
and the design (short dashed lines). The human bZIPs are: (b) JUN, (c) ATF2, (d) CEBPG, (e)
CREBZF, and (f) NFIL3.
Enhancing design performance with an N-terminal acidic extension
Vinson and colleagues have shown that replacing the basic region of several native bZIPs
with a designed sequence enriched in glutamates can provide potent dominant-negative
inhibitors of bZIP dimerization and DNA binding.7' 9' 10 They also showed that such an acidic
extension improved the affinity of a peptide rationally designed to heterodimerize with human
bZIP CEBPA.8 Because the basic region of BZLF1 is highly similar to that of human bZIPs (Fig.
2.1 a), we reasoned that incorporating an acidic extension into the N-terminus of our BD. design
might enhance its affinity for BZFL1.
Three acidic extension variants developed by Vinson et al. differ in 2 positions that could
interact with the BZLF 1 basic region, if the interaction occurred with a coiled-coil-like geometry
as has been hypothesized for other systems.7 We chose to use the "A"-extension, which
introduced the possibility of an attractive Glu-Arg g-e' interaction and a Leu-Leu core-core a-a'
interaction. Following prior work in the Vinson laboratory, we constructed A-BD (sequence in
Table 2.1). The modification added 17 residues at the N-terminus and replaced 6 out of 9 of the
most N-terminal residues of the designed region (Table 2.1). Interestingly, A-BD showed much
greater helicity than BD and BD , indicating that either some of the N-terminal 26 residues
and/or the distal C-terminal region are likely helical in this context (Fig. 2.3f). The Tm for A-
BD was similar to those for BD" and BD. (Table 2.1), whereas interaction with B-BZLF 1245
was significantly stabilized compared to the BD"/B-BZLF1"4 interaction as expected (Fig. 2.3f).
The heterocomplex melted at > 80 'C (Table 2.2). Together these observations indicate that
changes made in A-BD did not stabilize the design homodimer, but further enhanced its
interaction with B-BZLF 124, as desired for inhibitor design.
For comparison, we constructed several other peptides with acidic extensions and assessed
their self-association (Table 2.1). This modification dramatically destabilized BZLF 1245 by 28 'C
(71 'C for BZLF1 4 1 vs. 43'C for A-BZLF"14 1). A-BZLF1231 was also destabilized, but by only 10
0C (43 0C for BZLF 121 vs. 33 'C for A-BZLF 1211). BD14 was destabilized by an amount that
could not be quantified because A-BD did not exhibit a cooperative melt. A-BZLF 1245 was
tested for interaction with B-BZLF 1145 and formed a heterocomplex with Tm of 74 'C (compared
to the Tm for B-BZLF 12" self-interaction, 67 'C, Tables 2.1, 2.2). The Tm for the heterocomplex
between A-BZLF1 31 and B-BZLF1231 was 58 'C (compared to the Tm for B-BZLF123 1 self-
interaction, 31 'C). These results are consistent with an interaction between the acidic extension
and the basic region stabilizing the heterocomplexes, and also with an unfavorable interaction
between the distal CT and the acidic extension, which is considered further in the Discussion.
Inhibiting DNA binding by BZLF1
We used an electrophoretic mobility shift assay (EMSA) to assess inhibition of B-BZLF 1245
binding to DNA by different designed peptides (Fig. 2.6). The dimerization domain of BZLF 1
lacking the basic region, BZLF 1"", was included for comparison purposes. All peptides tested
showed concentration-dependent inhibition. BD 2c, A-BZLF 1" and A-BD21s were more effective
than BZLF 1". Design BD 21 was also an effective inhibitor. The most potent inhibitor was A-
BDc, which completely inhibited B-BZLF 1binding to DNA at equi-molar concentration.
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Figure 2.6 Peptide inhibition of B-BZLF1 245 binding to DNA.
Representative gel-shift images were shown for: (a) BZLF1245 , (b) A-BZLF1 245 , (c) BD24, (d)
245 245A-BDcc, (e) BDIED. The first two lanes for each gel include DNA only (first lane) and B-
BZLF1245with DNA (second lane). Inhibitor peptides were added in increasing concentrations
from 10 nM to above 2 ptM (left to right, 2-fold dilutions). Conditions are described in Materials
and Methods in more detail, and were slightly different for panel (a)-(d) vs. panel (e).
Discussion
In this study, we employed different design strategies to create inhibitor peptides targeting the
viral bZIP protein BZLF 1. We sought peptides that achieved hetero-specificity through enhanced
affinity for the target and/or reduced self-interaction. Below we discuss our different design
245 
>
BODED
approaches and the experimental behaviors of our designed peptides.
Applying CLASSY to BZLF1
As demonstrated earlier,'8 CLASSY is an algorithm that can be applied to design bZIP-like
coiled coils. It was developed in conjunction with a specialized scoring function that includes
computed structure-based terms, helix propensities, and experimentally determined coupling
energies. The scoring function was validated on a large-scale dataset of human bZIP coiled-coil
interactions13 and supported the successful design of numerous bZIP-binding peptides. It is not
known to what extent the bZIP scoring function can be applied in design problems involving
coiled-coil targets with features not observed in typical human bZIPs. Here, we explored whether
the BZLF1 dimerization domain could be treated as a standard bZIP target for CLASSY design.
To treat BZLF1 as a coiled coil, we designed against the N-terminal part of the sequence and
did experimental tests using constructs that did not include the distal CT (the "231" constructs,
Fig I b, 2a), much of which is not observed in the X-ray structure. The BZLF1 coiled-coil region
is rather short (4 heptads), has only one Leu at position d among these heptads, and includes a
region with very narrow inter-helical distance (~4 A Ca-Ca distance at a-position residue 204).
These variations might be expected to compromise performance of the scoring function, as
coiled-coil context is known to influence the contributions of residues and residue pairs to
stability. Thus, methods validated using human bZIPs might not generalize broadly to all
coiled-coil dimers. However, we found that design BD incorporated elements very commonly
employed in published anti-human bZIP designs (see below), and that these gave good
experimental performance in this less canonical example. Success might be attributed to the fact
that introducing more canonical residues at interfacial sites on one helix (the design) makes the
design-target heterodimer more similar to the human bZIPs, e.g. the heterodimer likely has a
more typical helix-helix separation.
Features contributing to the stability and specificity of the designs
Analysis of the designed sequences suggests that stability and specificity were achieved using
different combinations of core, edge and core-edge interactions. For example, in the BD" design,
the a and d heptad positions were populated with hydrophobic Ile and Leu, respectively, (e.g.
Y200L, A2041, K207L), which are expected to be exceptionally stabilizing in the design
homodimer.39 Therefore, a strategy that used only these mutations to stabilize the design-target
interaction would likely stabilize the design self-interaction even more, and fail to achieve
heterospecificity. Negative design elements that likely compensate for over-stabilization of the
design self-interaction come from interfacial e and g positions occupied by negatively charged
amino acids. These negative charges make favorable interactions with positively charged
residues in the target (e.g. 201R, 207K), consistent with improving the stability of the design-
target interaction. However, they also introduce repulsive g-e' or e-g' interactions in the design
homodimer (e.g. 196E-201E (g-e '), 203E-208E (g-e'), 201E-203E (e-g')). Similar examples of
using a highly hydrophobic core to achieve stability while modulating specificity using
interfacial charge have been observed in many prior coiled-coil designs. 32 One less familiar
feature in the BD" design is the presence of an N-terminal glutamate at a d position. Two
glutamate residues at d and d' in a homodimer are destabilizing in coiled coils,4 0 but this residue
potentially interacts favorably with an e' lysine in BZLF 1, via a core-to-edge type interaction
that has previously been noted in CLASSY-derived designs and other studies. 17,18,41,42,43
Designs BD.. and BD"' relied much more on core-to-edge interactions, which were placed
close to the middle of the coiled coil in these designs. In contrast to g-e' interactions, no coupling
energies have been measured for negatively charged residues at d-d' or d-e' sites. CLASSY
performed poorly in predicting the relative stabilities of complexes involving BD"' and BD",
most likely because experimental data describing such charged core-core and core-edge
interactions were not available to guide the development of the scoring function.
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Nevertheless, a cluster of 4 negatively charged residues in the design homodimer proved very
effective as a negative design element; BD"' and BD"' did not appreciably self-associate.
Affinity for the target was also compromised, however. Substitution of alanine with isoleucine at
a position 204 was introduced to compensate for some of the lost stability of the heterodimer,
showing how a different combination of stabilizing and destabilizing elements can generate a
hetero-specific design that inhibits DNA binding (Fig. 2.6).
Substitution of isoleucine for alanine at a position 204 is found in all 3 designs. In the native
structure, alanine at this position fits well in the tight space between unusually close helices (-4
A Ca-Ca distance between residue 204 on the two chains). Isoleucine cannot be built into this
site in the crystal structure without severe clashes. Nonetheless, the larger Ile was accommodated
in all three designs, and an alanine to isoleucine mutation is stabilizing in the context of
BZLF1245 (an increase of Tm by 9 *C under the conditions of Table 2.1, data not shown). These
data suggest a change in the backbone structure upon making this substitution. Local
rearrangement of the design-BZLF 1 complex to a more typical backbone structure probably
helps explain why the CLASSY bZIP scoring function worked well. To achieve good predictive
ability for a wider range of backbone structures, backbone flexibility could be treated
explicitly.43'
The influence of the distal CT region
Previous studies revealed that the distal CT, although unresolved in the BZLF 1 crystal
structure, might interact with the N-terminal part of the BZLF 1 coiled-coil region, thereby
stabilizing the dimer.27 We confirmed a stabilizing role for this region (Table 2.1, comparing
BZLF 231 and BZLF 1245). Interestingly, this effect depends on the sequence in the coiled-coil
region (Table 2.1, 2.2). The distal CT does not stabilize the BD. design self-interaction, and it
enhances the stability of the BD"j-target interaction only modestly. On the other hand, the distal
CT significantly increased the stability of the BD"" design self-interaction, as well as the
stability of the BD2 -target interaction. There are more sequence changes in the BDcc design,
and the number of negative charges introduced is larger than in the BDIED design. As discussed
below, the influence of the distal CT is also sensitive to the acidic extension included in some
designs. Although the structure of the interaction between the distal CT and the N-terminal part
of the coiled coil in the native protein is not known, repulsive electrostatics, or unfavorable
desolvation of charges in the coiled-coil region are plausible mechanisms for disfavoring this
interaction in the BDcc design.
Specificity against human bZIPs
We did not consider specificity against human bZIPs in our design procedure. However, we
showed that the design BDcc is not promiscuous in binding human bZIP proteins. Computational
analysis predicted that the coiled-coil region of BDcc would interact with the BZLF 1 coiled coil
moderately more favorably than with any other human bZIP coiled coil (but with a few close
competitors). This is interesting, given the fairly canonical coiled-coil sequence features of BDec.
The requirement to satisfy hydrogen bonding for Asn 204 at the a position in BDcc, and the
charge complementarity between the e and g positions of BDec and BZLF 1 helices but not most
human proteins, contributed to the predicted binding preference.
Thermal stability studies confirmed that BD24 does not bind strongly to selected human
bZIPs identified in the computational analysis. In addition to selectivity derived from the coiled-
coil region (which was predicted to be modest), the CT region likely confers additional
specificity. Interactions with BD2" and B-BZLF 1"" could benefit from native-like contacts
between the CT region and the coiled coil domain, which are not conserved in complexes with
human proteins. Thus, the interaction specificity of BD24 is likely encoded in both its coiled-coil
domain and the CT region.
Improving inhibitor potency using an N-terminal acidic extension
The Vinson group has demonstrated that dominant-negative inhibitors of bZIP dimerization
and DNA binding can be created by replacing the basic region of native or modified native bZIPs
with an acidic sequence.7 In this study, we used this strategy to improve the potency of our
designed peptides. The resulting A-BD24c peptide maintained specificity, showing little change in
the Tm for the design self-association. The small change in homodimer stability probably results
from destabilization by the negative charges in the extension, countered by a stabilizing leucine
residue introduced at d position 193 (this residue is Glu in BDec). 9 A-BDc" formed a more stable
complex with the target B-BZLF 1245 than did BD24c (an increase of Tm > 14 'C at 4 gM, Table
2.2). This indicates that the acidic extension, which targets the basic region of bZIPs, can be used
in conjunction with computational design methods targeting the coiled coil. Given that the
Vinson laboratory has demonstrated that the coiled-coil region of A-ZIPs governs interaction
specificity, while the acidic extension provides much enhanced affinity, this is an appealing
strategy for expanding the design of tight-binding and selective bZIP inhibitors.7 8 9 10' 18
Interestingly, modifying BZLF 1 with an acidic extension did not stabilize interaction of A-
BZLF 1245 with B-BZLF 1245 as much as expected (Tm of 74 'C compared to 67 'C for the B-
BZLF 1245 homodimer, Table 2.1, 2.2). In contrast, interaction of the shorter construct A-BZLF 12"
with B-BZLF 1231 was stabilized to a much greater extent (Tm of 58 'C compared to 31 'C for the
B-BZLF 123' homodimer). Furthermore, the destabilizing effect of the acidic extension on design
homodimer stability is quite different in BZLF 1245 vs. BZLF 1231 (decreasing Tm values by 28 'C
vs. 10 'C, Table 2.1). These observations are consistent with a model where the distal CT
interacts unfavorably with the acid extension, much as it appears to interact unfavorably with
negative charges in the N-terminal part of the BDcc design. Although not addressed in the
present study, the performance of A-BZLF 124 as an inhibitor could potentially be improved by
redesigning the acidic extension so that interference from the distal CT is minimized, although
this is difficult in the absence of structural information about this part of the protein.
Analysis of inhibitor potency
To test the designed peptides as inhibitors of BZLF1 DNA binding, we used an in vitro
EMSA assay to monitor the population of B-BZLF 12" bound to DNA in the presence of different
peptides (Fig. 2.6). It is unsurprising that A-BDc, which formed the most thermo-stable complex
with B-BZLF 1245 and exhibited the largest difference in homodimer vs. heterodimer stability, was
the most potent inhibitor. The improved performance of BD24' and A-BZLF 124" relative to the
native peptide, BZLF 1245, could be rationalized by their improved affinity and/or anti-homodimer
specificity (see below). BD 2, inhibited DNA binding effectively and we estimate its potency is
similar to that of BZLF 1245, although these two peptides could not be compared using identical
assay conditions (see Materials and Methods). The effectiveness of BD" resulted from a
combination of reduced affinity but improved anti-homodimer specificity.
To explore more generally how affinity and specificity each influence potency, we
constructed a simple computational model with the following assumptions: 1) the target bZIP, the
DNA, and the designed peptide were the only components present, 2) the target bZIP homodimer
was the only species that could bind DNA (i.e. complete cooperative binding), 3) non-specific
DNA binding was neglected. Some of the assumptions made may not apply to all of our
experiments. We computed concentration dependent inhibition of DNA binding for a series of
designs covering a spectrum of affinities and specificities. Affinity was described by the ratio
between the dissociation constant of the target bZIP homodimer and that of the design-target
heterodimer (KdT2/ KdDT, D: design, T: target, see Materials and Methods), and specificity was
described by the ratio between the dissociation constant for the design homodimer and that of the
design-target heterodimer (KdD2 / KdDT). The efficacy of different inhibitors is illustrated in a heat
map in Fig. 2.7 that indicates the improvement in IC 50 over a reference for which KdD2 = Kd DT
KdT2. The reference inhibitor with affinity and specificity of 1 was included to reflect the
behavior of the dimerization domain of the target bZIP. We explored two scenarios that led to
different inhibition landscapes: one where modeled dissociation constants for the target bZIP
complex and bZIP-DNA interactions were lower than the target bZIP concentration (Fig. 2.7a),
and another where they were higher (Fig.2.7b)
The results in Fig. 2.7 support intuition about the importance of both affinity and specificity.
Lines of constant color running across the plots in Fig. 2.7 show that equivalent potency can be
achieved using different combinations of affinity and specificity. Clearly, neither affinity nor
preference for hetero vs. homodimerization correlates directly with design performance. For the
purposes of discussion, we label 3 regions on the plots: Hamnnity:Lspec indicates inhibitors with high
affinity for the target but limited anti-homodimer specificity, Lainity:Hspec indicates inhibitors
with affinity for the target that is comparable to or weaker than the reference inhibitor, but with
weaker self-association, and Hafmnity:Hspec inhibitors have both tighter target-binding affinity and
weaker self-association than the reference. Among our designs, and to the extent that
approximate stabilities assessed by thermal denaturation under CD conditions can be
extrapolated to the gel-shift assay, BD" and BD 5 are both Lamnity:Hspec inhibitors that use anti-
homodimer specificity to improve inhibitor potency. A-BD maintains anti-homodimer
specificity but gains additional affinity via the acidic extension, making it a Hainity:Hspec inhibitor.
The model in Fig. 2.7 is useful for broadly guiding the computational design of specific
inhibitors, so we conclude with a few general observations. First, heterospecificity is important,
but not sufficient, for good performance. A design is hetero-specific if the ratio KdT2.K D /(KdDT) 2
is larger than 1. In the figure, this region is below the dashed line and all inhibitors with potency
better than the reference lie in this region. Maintaining hetero-specificity for high affinity designs
imposes a bound on design homodimer stability. This is relevant for parallel dimeric coiled-coil
targets, because amino-acid changes that enhance interaction with the target often stabilize the
design self-interaction even more.39 Second, the relative importance of improving affinity vs.
specificity depends on the target and assay conditions. For panel a, improved hetero-specificity
implies enhanced design performance regardless of whether affinity or specificity is the main
contributor. On the other hand, if the target bZIP concentration is lower, as in panel b, improving
specificity alone is no longer sufficient, and affinity must be optimized; very potent designs in
panel b can only be achieved by optimizing along the path toward Hamnityfspec. Finally, the
overall diagonal trends for constant-IC50 regions in both panels emphasize that improving either
affinity or specificity can potentially lead to success, depending on the specific conditions and
requirements for an application. Designs belonging to the Hamnityspec class are the most effective.
However, such designs might not exist, or could be hard to identify for a particular problem. In
such cases, one could consider optimizing primarily affinity or specificity, depending on which is
easier to achieve. Although not used extensively for this purpose here, the CLASSY algorithm is
well suited for identifying designs with different affinity vs. specificity trade-offs.18
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Figure 2.7 Inhibition of DNA binding as a function of the affinity and anti-homodimer
specificity of the inhibitor.
A description of the model is given in Methods. The ratio of the IC50 for a design to the IC50 for a
reference inhibitor with affinity equal to the wild-type protein is used as an indicator of design
potency (scale at right). This ratio is plotted as a function of the affinity and specificity of the
inhibitor. In (a), the Kd values for target dimerization and DNA binding are 10-fold lower than
the bZIP concentration. In (b) the Kd values for both associations are 10-fold higher than the
bZIP concentration. Labeling on the graph (HaLs: HaminityLspec, LaHs: Laffinitylspec and HaHs:
HaffinityLspec) is described in Discussion. The dashed line represents designs with zero hetero-
specificity. The reference inhibitor is indicated with a star.
Conclusion: implications for protein design
This study addresses three topics relevant to the design of peptides that inhibit native protein-
protein interactions. First is the issue of specificity, which arises in many protein design
problems and is acute for coiled-coil targets where self-association of the design can compete
with target inhibition. Using BZLF1 as a target, we characterized peptides that balance affinity
and specificity in different ways. This adds to the small number of examples where affinity and
specificity have both been treated as design considerations.' 8 , 41, 43, 45, 46, 47, 48, 49 Second, we
explored a design problem where features of the target that are not well described in an existing
structure (the BZLF 1 distal CT) nevertheless influence complex stability. We showed that
different designs responded differently to the introduction of the distal CT. This argues for
developing methods that broadly survey design solution space and discovering a large set of
potentially good designs, rather than identifying only "the best" design according to some
imperfect criteria. This can be accomplished in various ways, e.g. by exploring a range of
tradeoffs between stability and specificity, or exploring a variety of related structural templates
as design scaffolds.18 ' 50 Testing diverse solutions maximizes the chance of finding a design that
interacts well with poorly characterized features of the target. Finally, our best design exploited a
modular strategy where optimization of the coiled-coil dimerization interface was coupled with a
more generic strategy developed previously for stabilizing inhibitor-bZIP complexes. Modularity
is likely to be a key strategy for the design of ever more complex molecular parts.
Materials and Methods
Cloning, protein expression and purification
Synthetic genes encoding native or redesigned BZLF 1 sequence, residues 175 or 191 to 245
(B-BZLF1"4 , BZLF1"", BDcC, BDI), were constructed by gene synthesis. Primers were
designed using DNAWorks, 5 1 and a two-step PCR procedure was used for annealing and
amplification. Genes encoding the native or redesigned sequence in the context of residues 191
to 231 were made in a single-step PCR reaction using the longer constructs as templates. The
genes were cloned via BamHI/XhoI restriction sites into a modified version of a pDEST17
vector that encodes an N-terminal 6xHis tag and a GESKEYKKGSGS linker that improves the
solubility of the recombinant protein.28 To facilitate cloning of genes encoding the acidic
extension, a pET 1 6b vector (Novagen) was modified to encode an N-terminal 6xHis tag,
followed by a GSY linker and the acidic extension sequence. Genes encoding BZLF ,
BZLF 12" and the designs BD24c and BD..D were subsequently cloned into the modified vector
using AflII/XhoI restriction sites to make A-BZLF1 231, A-BZLF 1245, A-BD24 and A-BD 24 D
Recombinant proteins were expressed in E. coli RP3098 cells. Cultures were grown at 37 *C to
an OD of ~0.4-0.9, and expression was induced by addition of 1 mM IPTG. Purification was
performed under denaturing conditions (6M GdnHCl) using an Ni-NTA affinity column followed
by reverse-phase HPLC. Human bZIP constructs containing the basic region and the coiled-coil
domain were described previously.2 8
Computational protein design using CLASSY
The sequence BDc was designed using the CLASSY algorithm as previously reported.18 In
brief, the algorithm solves for the sequence predicted to interact most favorably with a target
sequence (here, chosen to be the N-terminal part of the BZLF 1 leucine zipper, residues 191 to
209) using integer linear programming. It is possible to impose constraints on the gap between
the energy of interaction with the target and the energy of undesired states such as the design
homodimer. No such constraint was applied in the design of BDec, which was predicted to favor
the design-target interaction over design homodimerization without it. The scoring function used
was HP/S/Cv. This function was derived by combining molecular mechanics calculations and
experimentally determined coupling energies for many core a-a' interactions. 13, 16 The Leu-Leu
core d-d' interaction was modeled with an empirical value of -2 kcal/mol-1. The HP/S/Cv
structure-based energy function was transformed into a sequence-based expression using cluster
expansion, and modified using empirical data, as described by Grigoryan et al.' 8
Predicting interactions between BDc and human bZIPs
BZLF 1 was aligned with 36 human bZIPs using the conserved basic region, and interaction
scores for residues 191-221 of BDc with the correspondingly aligned 31 residues of each human
bZIP were computed using the HP/S/Cv model as described above.
Circular dichroism spectroscopy
Circular dichroism experiments were performed and analyzed, and Tm values fitted as
described previously.18 Thermal melts from 0 00 to 85 0C were mostly reversible, regaining
>95% of signal or giving closely similar Tm values for the reverse melt (except for samples
containing NFIL3, which precipitated upon heating to 85 0C). Melting temperatures were
estimated by fitting the data to a two-state equilibrium (unfolded/folded), assuming no heat
capacity changes upon folding. A detailed description of the equation was described previously.
18 In cases where high-temperature unfolding precluded accurate fitting of unfolded baselines,
the Tm was either defined as the mid-point of the unfolding transition after manually picking the
baseline (for the 1:1 mixture of B-BZLF 12" and A-BZLF 1l"), or a lower bound on the Tm value
was estimated (for the 1:1 mixture of B-BZLF 12" and A-BD"). The protein concentrations are
given in the figure legends. All measurements were performed in PBS buffer containing 12.5
mM potassium phosphate (pH 7.4), 150 mM KCl, 0.25 mM EDTA and 1 mM DTT. Samples
were heated to 65 *C for 5 minutes before measurement to equilibrate peptide mixtures, and then
cooled to and equilibrated at the starting temperature.
Analytical ultracentrifugation
Protein samples were dialyzed against the reference buffer (12.5 mM sodium phosphate, 150
mM NaCl, 1mM DTT, 0.25 mM EDTA, pH 7.4) three times (including once overnight) before
measurements. Sedimentation equilibrium runs were performed with a Beckman XL-I analytical
ultracentrifuge using interference optics. Two concentrations for each protein sample were
prepared (50 and 100 pM), and runs at 3 different speeds (28,000, 35,000 and 48,000 rpm) were
carried out at 20 *C. Each run was ~ 20 h, and equilibrium was confirmed by negligible
differences between the sample distribution in the cell over sequential scans. Data were analyzed
globally with the program HeteroAnalysis5 2 , using a calculated 53 partial specific volume of
0.7275 ml/g (for the BD"c/BZLF 1" mixture) or 0.7245 ml/g (for BD"c) and a solution density of
1.005 g/ml.
Electrophoretic mobility shift assay (EMSA)
Gel shift assays were performed as described previously 2 8. Briefly, 10 nM B-BZLF 1245 was
prepared either alone or mixed with each inhibitor at 9 concentrations ranging from 10 nM to
2560 nM in 2-fold dilutions. Gel-shift buffer ((150 mM KCl, 25 mM TRIS pH 8.0, 0.5 mM
EDTA, 2.5 mM DTT, 1 mg/ml BSA, 10% (v/v) glycerol, 0.1 pig/ml competitor DNA (Poly
(I)-Poly (C) (Sigma))) was then added and incubated for 10 minutes at 42 'C. Closely similar
results were obtained when incubating samples for 20 minutes at 42 'C. The competitor BDED
was not stable upon heating and was incubated for 2 hours at 18-22 'C. Radiolabeled annealed
AP-1 site ,CGCTTGATGACTCAGCCGGAA (IDT), at a final concentration of 0.7 nM was
added and incubated for 15 minutes at 18-22 'C. Complexes were separated on NOVEX DNA
retardation gels (Invitrogen). Dried gels were imaged using a phosphorimaging screen and a
Typhoon 9400 imager. ImageQuant software (Amersham Biosciences) was used to quantify band
intensities.
Simulating the impact of affinity and specificity on designed peptide behaviors
The simulation treated the following species: The target bZIP monomer (T), the target bZIP
homodimer (T2), the design monomer (D), the design homodimer (D2), the design-target bZIP
heterodimer (DT), free DNA (DNA) and the complex formed between the target bZIP
homodimer and DNA (T2DNA). Species are linked by the following reactions:
<T T_ [T]2  T22T T2 =K1 rz
[D] 2  D22 D Dz = Kdz[D2]1
[D][T] DTD +T DT [D]= Ka(DT]
T2 + DNA C T2DNA [T2 ][DNA] KT2DNA[T2DNA] d
[T] + [DT] + 2[T2] + 2[T2DNA] = [T]totai
[D] + [DT] + 2[D 2] = [D]totai
[DNA] + [T2DNA] = [DNA]totai
Affinity is defined as KdT2 / KdDT, and a value > 1 indicates the design-target bZIP heterodimer
is more stable than the target bZIP homodimer (improved affinity). Specificity is defined as KdD2
/ KdDT, and a value > 1 indicates the design-target bZIP heterodimer is more stable than design
homodimer (improved specificity). A design with affinity and specificity equal to 1 was used as a
reference. The IC50 value was defined as the design concentration [D]total at which 50% less DNA
is bound relative to zero design concentration. The total target bZIP concentration [T]total was
fixed at 10 nM, and the total DNA concentration [DNA]total at 0.7 nM. Different combinations of
KdT2 and KdT2DNA values were explored (10-, 10-8, and 10- M for each), including when both are
lower than [T]totai (10-9 M/10~9 M, Fig. 2.7a) and when both are higher than [T]totai (10-7 MI0-1 M,
Fig. 2.7b). For each combination of fixed KdT2 and KdT2DNA, the IC50 values for a range of designs
with different affinities (0.1 to 10) and specificities (0.1 to 100) were calculated. The ratio
IC5 0 desin/IC5 0 re. with a value < 1 implying greater potency than the reference, was plotted as a
heat map. The dashed lines on the plots in Fig. 2.7 indicate points where the product of affinity
and specificity ((KT2 * Kd D2)/(KdDT * KdDT)) equals 1. All designs below the dashed line are
hetero-specific. The simulation was carried out and heat maps were generated using Matlab
(MathWorks).
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Chapter 3
Design of anti-apoptotic Bcl-2 proteins with novel interaction
specificity toward different BH3 peptides
This work is currently being prepared as a manuscript to be submitted later
Collaborator notes:
Hector Palacios cloned and purified some of the recombinant BH3 peptides and
cloned the first designed library.
Introduction
Engineering protein-protein interactions is critical to numerous areas of basic science and
12biotechnology. Designed proteins can be used to inhibit or activate other proteins' , to alter
native proteins to study their functions3'4, or to create novel interactions that rewire cell signaling
5,6in synthetic biological systems' . Many design applications demand that interactions be specific,
i.e. that designed proteins interact only with target proteins and not with off-targets. This adds an
additional layer of complexity to what is already a difficult design challenge.
Commercially useful interaction reagents and therapeutics are almost always identified by
screening large combinatorial libraries, which can be an inefficient process due to the enormity
of sequence space. Recent progress in computational design7 ,8' 9 offers great promise to accelerate
the discovery of protein reagents with desired properties, by predicting good binders at the outset.
But current methods are limited by available binding models. Contemporary physics based
structural models enjoy the advantage of being general, but are computationally inefficient and
not always accurate 0'11, while models that include statistical terms derived from known
structures2 can address some of these deficiencies but still do not provide high confidence in
results. Methods relying on evolutionary sequence analysis or machine learning1 4 can only be
applied for protein families that satisfy certain criteria (e.g. having a large number of protein
sequences with known interaction properties).
Recently, several groups have proposed and tested the idea of computationally designing a
library of protein sequences523. The rationale is that given the imperfect models used in protein
design, assaying a large number of designed sequences simultaneously will increase the overall
success rate. Previous studies have suggested several important factors to be considered for
library design. These include whether the library can be cloned cost-effectively1 9 , whether the
library is adequately covered by the experimental screening platform 17,18,19, and the diversity of
17,22. -o22.Freap,
the library sequences172. Trade-offs exist when considering these factors . For example,
including more diverse sequences can lead to a library size larger than is practical to assemble or
screen.
In this study we examined these issues in the context of designing protein-protein interaction
specificity. Specificity design imposes multiple objectives, i.e. binding to one desired target but
not to a related competitor. The demands on the accuracy of any binding model are high, and the
risk of designs not working as expected is also high2 4 . Here we present a novel library design
strategy that emphasizes maintenance of a high degree of useful diversity, as predicted by an
imperfect model. Our framework consists of two stages. In the first, desired sequence features
12are predicted using the structural modeling software Rosetta 1. Desired sequence features are
defined permissively, and emphasize the selection of residues predicted to maintain binding to a
desired target. In the second stage, we apply the optimization algorithm integer linear
programming (ILP) to design a combinatorial, degenerate codon based DNA library encoding
the desired sequence features. Different constraints, such as an upper limit on library size, can be
introduced easily into the ILP optimization, making it possible to rigorously explore the different
trade-offs in library design as described above.
We applied this framework to the design of anti-apoptotic Bcl-2 proteins with novel peptide
interaction specificity. The anti-apoptotic Bcl-2 family25 proteins have a globular, helical fold
and bind to short helical peptides derived from pro-apoptotic proteins, here called BH3 peptides.
Native Bcl-2 family proteins bind BH3 peptides with a range of different specificities26 27 . We
aimed to re-design anti-apoptotic protein Bcl-xL so that it would lose the ability to strongly
interact with BTI3 peptide Bim but still bind tightly to a BH3 peptide derived from Bad. This is
an interesting specificity design problem because all known anti-apoptotic Bcl-2 proteins interact
strongly with Bim, which is proposed as an "activator" BH3 28 in some models of the regulation
of apoptosis 28,29,30 . In contrast, the BH3-only protein Bad, proposed as a "sensitizer", interacts
with the anti-apoptotic proteins in a more selective manner. We designed libraries of Bcl-xL
variants and screened these using yeast surface display3 1. We successfully obtained Bcl-xL
variants that showed a strong preference for binding Bad over Bim. Detailed investigation of the
sequence characteristics revealed that our inclusive design strategy was crucial for identifying
high specificity sequences. We further showed that our designed protein is globally specific
against binding 10 other BH3-only peptides not considered in library design, with interesting
implications for specificity design involving multiple off-targets.
Results
Library design
There are two stages in our library design procedure (Fig. 3.1A). In the first stage, desired
sequence features were identified. To simplify the analysis, we defined sequence features as
individual residues, making the assumption that the energetic contribution of an amino acid at a
given position is independent of its sequence context. This left the screening experiments to
identify/avoid potential higher order interactions among residues at different designed positions,
eliminating the possibility that such information could be predicted and used for making a more
efficient library. The implications of this are considered further in the Discussion.
Guided by crystal structures of complexes between Bcl-xL and Bim/Bad32 ,33 , we chose 9 Bel-
xL sites where contacts are made to the central part of the Bim/Bad BH3 peptide for redesign.
These 9 positions mostly interact with BH3 positions occupied by different amino acids in Bim
vs. Bad (Fig. 3.1B, 3.1C). We next used the structural modeling suite Rosetta to predict how
different amino acids at each Bcl-xL designed position, in the sequence context of Bcl-xL, could
affect interaction with Bim or Bad. Amino acids to be modeled at each position were chosen
manually by considering factors such as hydrophobicity and size. Modeled complexes between
different Bcl-xL point mutants and Bim or Bad were generated and their Rosetta energy scores
relative to that of the native amino acid, AEBim and AEBad, were obtained (see Materials and
Methods).
A IPickdesine B
C
Bim: MRPEIWIAQELRRIGDEFNAYYARRVFL
Bad: LWAAQRYGRELRRMSDEFVDSFKKGLPR
Figure 3.1 Library design protocol
(A) The library design protocol. Non-disruptive and specific residues were predicted at every
designed position, and ILP optimization was performed to select degenerate codons that together
maximize the inclusion of non-disruptive residues while enforcing the inclusion of specific
residues, under a library size constraint. (B) The interface between Bcl-xL and a Bim BH3
peptide (PDB ID: 3FDL), with Bcl-xL shown in cyan and the peptide shown in orange sticks
(PyMol, Delano Scientific). Designed positions for the first library are blue, while those for the
second library are red. (C) A sequence alignment of the Bim (residue 142 to 169) and Bad
(residue 104 to 131) BH3. Positions occupied by different amino acids and exploited for Bcl-xL
design are colored in blue (for the first library) or red (for the second library).
Based on this analysis, we indentified non-disruptive residues that were predicted not to
greatly disrupt binding to the desired target Bad. This is a less stringent and more inclusive
prediction criterion than demanding that residues contribute to binding specificity. We argued
that energies above a certain threshold could imply serious steric clashes or under-packing in the
modeled complexes, and defined a AEBad value to serve as a cutoff for non-disruptive residues
(Table 3.1). We also tabulated the difference in Rosetta energy scores for the modeled complexes
between the corresponding Bcl-xL point mutant and Bim/Bad (AEBim - AEBad). Residues with a
score difference above a certain threshold were predicted as specific residues that could
contribute to the desired interaction specificity of Bad over Bim (Table 3.1). It should be noted
that the specificity residues are a subset of the non-disruptive residues.
Table 3.1 The first designed library
Position residues modeleda residues encodedb
F97 AFGILEV FILM (WTK)
Y101 AFGI MTVY FHLY (YWT)
A104 ANGI ACDEFGIKLMNRSTVWYZ (DNK)
L108 AFGILMV AGILPRSTV (VBT)
L112 AFGILME LMV (DTG)
V126 AFg] AGIMRSTV (RBK)
E129 &EITV AEIKTV (RHA)
L130 AFGLMS ILV (VTC)
A142 A TV AGST (RSC)
a Residues modeled at each position. Underlined residues were predicted to be non-disruptive,
shaded residues were predicted to be specific.
b Residues included in the designed library (encoded by the degenerate codon in parentheses). A
stop codon is indicated by "Z". The IUBMB abbreviations for mixture of nucleotides were
adopted when representing the degenerate codons.
We proceeded to design a library, i.e. to optimize combinations of degenerate codons
encoding diversity at each designed position. We formulated the optimization problem as an
integer linear programming (ILP) problem. The objective to be maximized was the number of
unique library sequences with designed positions all occupied by non-disruptive residues. This is
the product of the number of non-disruptive residues encoded by the degenerate codons across
all designed position. Note that this objective could also be loosely interpreted as the number of
unique protein sequences predicted to bind the desired target Bad. We enforced two constraints
in the ILP problem. The first was on the library size in DNA space, which was set to 107 , a
conservative estimate for obtaining good sequence coverage in yeast surface display. The second
was that all predicted specificity residues as well as all native residues were required to be
included in the library. Both the objective and the size constraint are products and become linear
in logarithm space, making the problem amenable to the ILP optimization (see Materials and
Methods). The optimized library (Table 3.1) had a size of 8.9*106 and contained 2.2* 105 unique
protein sequences predicted to bind Bad, about -6% of all library DNA sequences encode
protein sequences predicted to bind Bad.
Yeast surface display screening
We used yeast surface display for the experimental screening. Native Bcl-xL displayed on the
yeast surface bound both the Bim and Bad BH3 domains strongly, but did not bind the Noxa
BH3 domain (data not shown), agreeing with previous binding studies done in solution. The
designed library was enriched in sequences binding Bad, as expected. Approximately 5% of the
population showed binding at 10 nM Bad BH3 (Fig. 3.2A). Interestingly, the designed library
bound a Bim BH3 peptide even better than Bad (Fig. 3.2A), and this is discussed further below.
The designed library was subjected to 6 rounds of screening to identify Bcl-xL variants that
bound Bad in preference to Bim (see Materials and Methods). The final population showed
significantly enhanced specificity, with binding to Bad detectable at 1 nM Bad BH3, but that to
Bim detectable only at 100 nM (Fig. 3.2B). Characterization of 48 clones randomly selected
from this population gave 21 unique clones with stronger binding signal under 1 nM Bad over 10
nM Bim (Fig. 3.2C, Table 3.2). The results revealed one Bcl-xL designed position, 142, at which
substitution of Ala to Gly (A142G) was found in all sequences. Some designed positions were
occupied by both native and non-native amino acids across all sequences, whereas some were
occupied only with the native amino acid. A more detailed examination of the emerging
sequence features and how they relate to the ones predicted in the library design is presented in
the Discussion.
A Library 1 before sorting B Library 1 after six rounds of sorting
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Figure 3.2 The first designed library
(A) Flow cytometry plots showing the first designed library displayed on the yeast surface
binding Bad (top) and Bim (bottom) at 1 piM and 10 nM. (B) Flow cytometry plots showing the
final sorted population from the first designed library displayed on the yeast surface binding Bad
(top) and Bim (bottom) at 100 nM, 10 nM and 1 nM. (C) Sequence frequency plot for 21 unique
sequences identified as specific for Bad over Bim BH3 from the first designed library (Table 3.2),
45
w te nie Bel-x r shw be e ol Pl40oo wee genera tes
Web IRogo*5.
Table 3.2 Unique sequences isolated from the first designed library
A2
A3
A4
B2
B4
B5
C1
C3
C4-
C5
C6
D3
D5
D6
E2
E5
F4
G3
G5
H3
H6
F97
F
F
F
F
F
F
F
F
F
F
L
F
F
F
F
F
F
F
F
F
F
Other"Y101
Ya
Y
YY
Y
Y
a Shaded residues were either not included in the modeling or not predicted as "non-disruptive"
residues, but were included in the library due to degenerate codons.
b Residues under the "other" column were not included in the library design.
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Design and screening of a second library with improved specificity
Based on the promising results of the library screen, we proceeded to design a second library
to identify sequences with further improved specificity. Using the same structural modeling
protocol described above, we predicted non-disruptive residues and specificity residues for 6
additional Bcl-xL positions (Fig. 3.1B, Table 3.3). These new positions were mostly located at
the edge of the BH3-binding interface, and not surprisingly, our very relaxed definition of non-
disruptive residues included almost all residues. Among the 9 designed positions screened in the
previous library, we fixed position 142 as Gly (A142G), whereas position 97 and 112 were
reverted back to the native residues. Non-disruptive residues at the other 6 positions (101, 104,
108, 126, 129, 130) were redefined as amino acids with significant frequency in the first round of
screening (Fig. 3.2C, Table 3.2). A total of 12 Bel-xL positions were randomized in the new
library. The same ILP library optimization procedure described previously was carried out to
select degenerate codons for these positions. To increase efficiency in encoding amino-acid
diversity, we introduced a slight modification to allow some designed positions to be encoded by
a pair of degenerate codons rather than just one, subject to constraints imposed by the PCR
assembly protocol (See Materials and Methods).
Significant improvement in specificity was observed after two rounds of screening the newly
designed library (Fig. 3.3A). Sequencing results revealed strong sequence bias at several
designed positions (Fig. 3.3B, Table 3.4), as discussed below. We performed 5 additional rounds
of screening, and the final population was highly specific for binding Bad over Bim (Fig. 3.3D),
showing good binding to Bad at 1 nM Bad BH3 but much lower binding to Bim BH3 at 1 ptM.
Only 2 sequences were present in this population, L2-7-Al and L2-7-F1 (Table 3.5). Each
contained 9 mutations from native Bcl-xL, and the mutations were consistent with residues
observed at high frequency after two rounds of screening, as shown in Fig 3.3B. Interestingly,
both sequences contained a mutation (F105L) not present in the designed library. The effect of
this mutation was investigated and analyzed below.
Table 3.3 The second designed library"
residues modeled
ADEFGHIKLMNQRSTVY
EDF QRS Y
ADEF KLMNORSTVY
ADEFGHIKLMNQRSTVY
AFGILMV
FY
HY
AFMW
LRTV
AV
ETV
LI
residues encoded
EGLQRV (SDA)
ADEGHIKLMNPQRSTV (VNK)
ADFHILNPSTVY (NHC)
ADEFGILNQRSTVY (DHTSDA)
AFL (TTSGCT)
FY (TWC)
HY (YAT)
AM (GCAATG)
LV (STG)
AV (GYA)
EV (GWA)
LI (MTC)
a See descriptions for Table 3.1.
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Figure 3.3 The second designed library
(A) Flow cytometry plots showing the population after two rounds of sorting of the second
designed library displayed on the yeast surface binding Bad (top) and Bim (bottom) at 1 gM, 100
nM, 10 nM and 1 nM. (B) Sequence frequency plot for 28 unique sequences (Table 3.4)
identified as specific for Bad over Bim BH3 from the second designed library. Mutations not
located at the intended designed positions were omitted from the plot but are listed in Table 3.4.
(C) Flow cytometry plots showing binding profiles of native Bcl-xL displayed on the surface of
yeast toward Bad and Bim at 1 nM. Expression and binding signals are plotted on the x and y
axes, respectively. (D) Flow cytometry plots showing binding of the second designed library
after 7 rounds of sorting toward Bad at 1 nM and Bim at 1 pM.
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Table 3.4 Unique sequences of specific binders isolated from the second designed library
after two sorts a
OtherE96
Q
L
Q
L
L
Q
Q
R
V
V
Q
Q
G
L
G
Q
Q
L
E
R
R
L
L
L
Q
L
Q
Q
a See descriptions for Table SI
Table 3.5 Sequences of clones from the final sorted population of the 2 "d designed library
E96 Y1la F105a Q111 S1221 Q125 V126 L130 A142 F146
Al E H L G I V A I G A
F1 L H L D T E A L G A
101
a Y101H was not included in the modeling but was included in library 1 due to codon choice.
Position 105 was not included in the designed library. All other residues were predicted to be
non-disruptive.
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Solution binding study
To confirm that the specificity profile of the selected Bcl-xL variants seen on the yeast
surface could be recapitulated with soluble, recombinant proteins, we used a fluorescence
polarization (FP) competition binding assay (see Materials and Methods, Fig 3.4, Table 3.7).
Native Bcl-xL interacted very strongly with both the Bim and Bad 28-mer recombinant peptides
(Bim-28 and Bad-28, Table 3.6), with fitted Kd values below 0.1 nM (Fig. 3.5A). The fitted Kd
values for L2-7-Al interacting with Bim-28 and with Bad-28 were 2.3 .iM and 0.25 nM,
respectively (Fig. 3.5B). The tightest binding that can be reliably quantified using our
experimental conditions is -0.1 nM. Thus, to more reliably measure the increase in specificity
from native Bcl-xL to L2-7-Al in solution, we turned to BH3 peptides of shorter length (22-mer)
expected to be of lower binding affinity. The shorter peptides (Bim-22 and Bad-22, Table 3.6)
maintained interactions with all of the designed Bcl-xL positions, based on crystal structures.
The fitted Kd values of L2-7-Al were > 50 tM and 33 nM, for Bim and Bad respectively,
suggesting a specificity increase of >1,000 fold for the designed protein (Fig. 3.5C, Fig. 3.6).
Dissection of residues important for specificity
To analyze how individual mutations at each designed position contribute to the binding
specificity of L2-7-A1, we made point mutations in Bcl-xL (Fig. 3.4, Fig. 3.5C) and also
individually reverted selected residues of L2-7-A1 back to the native Bcl-xL amino acid (Table
3.8). We examined binding of these variants to Bim and Bad BH3 peptides. In the context of
Bcl-xL (Fig. 3.5C), V126A, S1221 and A142G preferred binding Bad over Bim, while L1301 and
F146A weakened binding to both peptides and showed no strong preference. Y101H, L105F and
Q1 I1G actually displayed preference for binding Bim over Bad. When examined in the context
of L2-7-Al (Table 3.8), reverting 1122 back to Ser, G142 back to Ala, and surprisingly, A146
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back to Phe all caused significant loss of Bad over Bim specificity. The loss in specificity for L2-
7-Al-A 146F was particular interesting as it likely explained why the F146A mutation was
present in all specific sequences in library 2 (Fig. 3.3B) but did not confer specificity when
measured in the context of Bcl-xL (Fig. 3.5C). Interestingly, reverting the two mutations not
intended to be included as non-disruptive residues in the library, Y101H and L105F, caused
moderate loss in specificity as well (L2-7-Al-Hl0lY and L2-7-Al-L105F in Table 3.8), despite
favoring Bim binding over Bad when made in the context of Bcl-xL (Fig. 3.5C). Overall, the
analysis suggested that although some of the influences of the designed residues are relatively
independent of the sequence context, significant higher-order interaction among residues at
different positions was evident and contributed to the observed specificity.
Table 3.6 B
Bim-28
Bad-28
Bim-22
Bad-22
Bak
Bax
Beclin
Bid
Bik
Bmf
Hrk
Mule
Noxa
Puma
fBad-21b
fBad-23c
fBad-27'
H3 peptides used in this study
e fgabcde fgabcdefgabcde f gab
MRPEIWIAQELRRIGDEFNAYYARRVFL
LWAAQRYGRELRRMSDEFVDSFKKGLPR
MRPE IWIAQELRRIGDEFNAYY
LWAAQRYGRELRRMSDEFVDSF
SSTMGQVGRQLAIIGDDINRRYDSEFQT
DASTKKLSECLKRIGDELDSNMELQRMI
GGTMENLSRRLKVTGDLFDIMSGQTDVD
EDIIRNIARHLAQVGDSMDRSIPPGLVN
MEGSDALALRLACIGDEMDVSLRAPRLA
HQAEVQIARKLQCIADQFHRLHVQQHQQ
SSAAQLTAARLKALGDELHQRTMWRRPA
GVMTQEVGQLLQDMGDDVYQQYRSLTRQ
AELEVECATQLRRFGDKLNFRQKLLNL I
EQWAREIGAQLRRMADDLNAQYERRRQE
NLWAAQRYGRELRRMSDKFVD
Fl -NLWAAQRYGRELRRMSDEFVDSF
Fl -NLWAAQRYGRELRRMSDEFVDSFKKGL
Origina
recombinant
recombinant
synthetic
synthetic
recombinant
recombinant
recombinant
recombinant
recombinant
recombinant
recombinant
recombinant
recombinant
recombinant
synthetic
synthetic
synthetic
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aA detailed description of the constructs is included in Materials and Methods.
bThe FITC label is on the underlined Lys residue
c F 1 stands for FITC
Table 3.7 Fitted Kd values for direct binding experiments between Bcl-xL variants and
different fluorescently labeled peptides (fitted curves shown in Fig. 3.4)
Labeled Kd
peptide (nM)
Bcl-xL fBad-23 3.3
L2-7-A1 fBad-23 22
Y101H fBad-23 23
A104M fBad-21 3.8
F105L fBad-23 8.7
Q111G fBad-23 6.5
S1221 fBad-21 4.2
Q125V fBad-21 4.6
V126A fBad-23 15
L1301 fBad-23 31
A142G fBad-21 1.5
F146A fBad-23 61
L2-7-A1-H101Y fBad-23 2.9
L2-7-A1-L105F fBad-27 6.8
L2-7-A1-G111Q fBad-23 13
L2-7-A1-1122S fBad-27 40
L2-7-A1-G142A fBad-27 34
L2-7-A1-A146F fBad-23 21
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Figure 3.4 Fluorescence polarization experiments and fitted curves characterizing binding
of Bcl-xL, L2-7-A1 and different point mutants to fluorescently labeled Bad peptides.
Different labeled peptides used for different Bcl-xL variants were indicated on the plot and
described in Table 3.6. The averaged values as well as the spread of two independent
measurements of anisotropy were plotted as a function of Bcl-xL variant concentration.
Experimental conditions and curve fitting for the direct binding experiments are described in
Materials and Methods. Figure to be continued on the next page.
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Fig 3.4 (continued) Fluorescence polarization experiments and fitted curves characterizing
binding of Bcl-xL, L2-7-A1 and different point mutants to fluorescently labeled Bad
peptides.
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Figure 3.5 Fluorescence polarization experiments characterizing Bcl-xL and its variants
binding to BH3 peptides derived from Bim or Bad.
(A) Competition of Bim-28 and Bad-28 with fBad-23 in binding to native Bcl-xL. Binding
conditions are described in Materials and Methods, and peptide sequences are given in Table Si.
Fitted curves were not shown as the interactions were too tight to be fitted. (B) Competition of
Bim-28 and Bad-28 with fBad-23 in binding to the design L2-7-Al. For (A) and (B), the
averaged values as well as the spread of two independent measurements were plotted as a
function of competitor peptide concentration. (C) Kd values for Bcl-xL, L2-7-Al and different
Bcl-xL point mutants interacting with Bim-22 and Bad-22. Mutations that give the most Bad-
over-Bim specificity are highlighted in blue (The mutation A04M was not present in L2-7-A1).
The curves are shown in Fig. 3.5, and the fluorescent peptides being competed off are indicated
in Table 3.7.
Table 3.8 Kd values for point mutants of design L2-7-A1 binding Rim/Bad
Bad-22 Bad-28 Bim-28
L2-7-A1 33 0.25 2,300a
L2-7-A1-H101Y 4 - 200a
L2-7-A1-L105F - 1.3 1,500a
L2-7-A1-G111Q 17 - 1,400a
L2-7-A1-1122S - 7.0 3,200a
L2-7-A1-G142A - 7.6 430
L2-7-A1-A146F 39 - 130
aLimited solubility of Bim-28 at high concentration prevents accurate determination of the lower
baseline when fitting dissociation constants. Fitted values were obtained instead by imposing a
lower baseline as described in Materials and Methods.
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Figure 3.6 Fluorescence polarization experiments and fit curves characterizing binding of
Bcl-xL, L2-7-A1 and different point mutants to unlabeled Bim or Bad peptides by
competition.
Different fluorescently labeled peptides being competed off of different Bcl-xL variants were
shown in Table 3-6. The Bcl-xL or L2-7-A1 variant and the competitor peptides were indicated
on the plot. The averaged values as well as the spread of two independent measurements were
plotted as a function of competitor peptide concentration. Experimental conditions and curve
fitting for these competition experiments are described in Materials and Methods. Figure to be
continued on the next page.
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Figure 3.6 (continued) Fluorescence polarization experiments and fit curves characterizing
binding of Bcl-xL, L2-7-A1 and different point mutants to unlabeled Bim or Bad peptides
by competition.
Specificity profiles against other BH3s
We also evaluated interactions between L2-7-Al and 10 other peptides derived from the BH3
regions of human Bel-2 family proteins not included in the design/screening efforts. In contrast
to Bcl-xL, which interacts strongly with several other BH3s (Fig. 3.7A, 3.7C), significant
interaction was observed only between L2-7-Al and PUMA (Fig. 3.7B). The interaction of L2-7-
Al with PUMA was significantly weaker than that between Bcl-xL and PUMA (Fig. 3.7C). In
summary, L2-7-Al displayed global specificity against the other BH3s not included in
specificity screening.
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Figure 3.7 Fluorescence polarization experiments characterizing Bcl-xL and the design L2-
7-Al binding to 10 native BH3 peptides.
(A) Competition of different BH3s with fBad-23 binding to native Bcl-xL. (B) Competition of
different BH3 peptides with fBad-23 binding to the design L2-7-Al. For (A) and (B), the
averaged values as well as the spread of two independent measurements were plotted as a
function of competitor peptide concentration. Competition curves were shown only for
competitor peptides binding Bcl-xL significantly. (C) Fitted Ka values of Bcl-xL and L2-7-Al
interacting with different BH3 peptides.
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Discussion
The idea underlying our library design strategy was that maintaining high useful sequence
diversity is important when treating difficult design problems such as protein-protein interaction
specificity. The importance of diversity has been illustrated and discussed previously in other
contexts 17,22. In our approach, diversity is obtained by including predicted non-disruptive
residues in addition to specific residues at each designed position. We enforced the inclusion of
all predicted specific residues in our libraries, thereby providing access to a variety of possible
predicted specificity strategies. We also adjusted the inclusion of non-disruptive residues to
achieve the desired library size.
We compared the library screening outcomes and the behaviors of the Bcl-xL point mutants
with structural modeling results. Our library design procedure was successful in enriching the
library in Bad binders; compared to our prediction that 6% of library 1 lacked any disruptive
mutations, 5% of expressed library 1 sequences were observed to bind to 10 nM Bad (Fig. 3.2A).
Nonetheless, the performance of the specificity predictions suggested room for improvement in
the modeling protocol, which was tailored to be very inclusive in picking non-disruptive residues.
All 9 mutations in the selected L2-7-Al sequences were characterized as Bcl-xL point mutants
(Fig. 3.5C). The mutation S 1221 was predicted and confirmed to be specific. Two other specific
mutations, V126A and A142G, were included in the library only as predicted non-disruptive
residues. G1 11Q and L1301 were predicted but shown not to be specific. Two other non-specific
mutations, Q125V and F146A, were also predicted only as non-disruptive residues. However,
F146A likely played an important role in specificity as reversing the mutation in L2-7-Al caused
significant loss in specificity (Table 3.8). Y101H was not selected for modeling and F05L was
not included in the library. Neither of them was specific when characterized as Bcl-xL point
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mutants, but might contribute to specificity when combined with other residues, as observed
when examined in the context of L2-7-Al. For predicted specificity residues not present in L2-7-
A1, A104M was confirmed to be specific and appeared in some of the specific sequences.
However, most of the other predicted specificity residues were not present in the selected
specific sequences.
Given that many of the predicted specificity resides were in fact not specific, the broad
inclusion of non-disruptive residues in this application was crucial for capturing important
residues missed by the specificity predictions (e.g. V126A, A142G and F146A). The strategy we
chose had the caveat that many residues predicted to be non-disruptive would indeed not
contribute to specificity. In fact, as shown in Fig. 3.2A, the designed library showed on average
stronger binding to Bim than to Bad. Adjusting the inclusion of non-disruptive residues by the
desired library size was therefore important. We picked a conservative library size of 107 for
yeast surface display. However, the ILP optimization makes it possible to examine how relaxing
the library size constraint, with the risk of experimentally under-sampling the diversity, could
lead to a more comprehensive inclusion of the non-disruptive residues. One of the advantages of
the ILP formulation is that it allows the designer to explore trade-offs up front in this way,
knowing that the algorithm provides optimal solutions under the specified constraints.
Mutational analysis was also used to understand the origins of the high specificity of L2-7-Al
for Bad over Bim (Fig. 3.5C). Several single mutations conferred moderate to strong Bad-over-
Bim specificity (S 1221, Vi 26A and Al 42G), whereas others significantly weakened Bim
binding (Y101H, L1301 and F146A). However, this explains only part of the specificity, and
analysis of selected L2-7-Al mutants (Table 3.8) suggested that inclusion of higher order
interactions is likely needed to understand the complete picture as described in Results. If
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reliable predictions of higher-order coupling could be made, including them in library design
could increase efficiency. For example, Lippow et al. suggested the importance of explicitly
looking at higher-order interactions in the context of enzyme design20 . Coupling between codons
at different positions can be easily incorporated under the ILP formulation if desired 2 .
Interestingly, design L2-7-Al is not only specific against Bim, but also against all other
natural BH3s tested in this study. The only other BH3 peptide that showed significant interaction
with L2-7-Al was PUMA, which shares some features with Bad, such as Met at position 3d and
Ala (closer in size to Ser in Bad) at 3e (Table 3.6). Design examples where specificity was
obtained "for free", i.e. without explicit consideration, have been reported previously34 35 . In the
present case, specificity against Bim was not "free" but had to be introduced by screening; the
original library 1 bound strongly to both Bad and Bim. Elements that destabilize interaction with
Bim apparently also destabilize interaction with many other BH3 peptides. For challenging
multi-specificity design problems where it is impractical to screen against all relevant
competitors it might be reasonable to take the approach used here, as long as designed positions
are selected carefully to reach meaningful diversity as described before. An interesting analogy is
the study performed by Guntas et al. 36, which showed that a library enriched in predicted well-
folded sequences performed as well as one enriched in predicted binders when screening for
novel interaction partners. In contrast, design studies targeting bZIP coiled coils showed that
ignoring some competitors in design calculations could lead to undesired binding3 7. The degree
to which negative design is required appears to depend critically on the particular problem being
addressed38.
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Materials and Methods
Structural modeling
Structural models of Bcl-xL point mutants interacting with Bim or Bad were generated using
Rosetta 3.012. The crystal structure of human Bcl-xL in complex with Bim (PDB ID: 3FDL) 32
was used to model interactions between Bcl-xL mutants with Bim and Bad, and that of mouse
Bcl-xL in complex with Bad (PDB ID: 2BZW) 33 was used to model interactions between Bcl-xL
mutants with Bad only. An ensemble of 100 structures was derived separately from each of
3FDL and 2BZW, with fixed native sequence, using the backrub flexible-backbone modeling
utility in Rosetta39. The entire binding interface was allowed to change structure during the
backrub sampling. Each Bcl-xL mutant interacting with Bim or Bad was then modeled on all
members of the structural ensemble using the fixed backbone design mode in Rosetta. A 50-step
conjugate-gradient based minimization was performed for each ensemble member, and the
Rosetta energy for each minimized structure within the ensemble was obtained. The minimum
energy was defined as the score of the interaction between the Bcl-xL mutant being modeled and
Bim or Bad, and the difference relative to the score of native Bcl-xL interacting with Bim or Bad
was calculated (AEBim or AEBad). The unbound states were not modeled and the 20 single amino
acid reference energies in Rosetta were used as the reference state instead. The score should
therefore not be viewed as an attempt to predict whether the mutant would increase or decrease
the affinity of the interaction, but rather as a simple metric estimating if complex formation
would be greatly disrupted. Note that it is possible that a mutant could be predicted to disrupt
significantly the energy for both the complex and the unbound state. Such mutant would be
predicted to not disrupt the interaction and be missed by our protocol. On the other hand, mutants
predicted to strongly destabilize the unbound states might not be desired. As interactions
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between mutants with Bad were modeled using both 3FDL and 2BZW as templates, two values
of AEBad were generated and the lower one was picked as the final AEBad. Residues with AEBad
lower than 3 (for the first designed library) or 1 Rosetta energy unit (for the second designed
library) were defined as non-disruptive residues. Residues with AEBim - AEBad greater than 2 (for
the first designed library) or 3 Rosetta energy units (for the second designed library) were
defined as specificity residues. Here the omission of the unbound states should not influence the
specificity prediction as they would be canceled out regardless.
Position Y195 was not subjected to structural modeling as it was missing in the human Bcl-
Xl/Bim structure (3FDL). The corresponding position (Y195) was observed in the mouse Bel-
xL/Bim structure (1PQ1) and formed a hydrogen bond with N102 (position 4b in the BH3
alignment) of Bim (occupied by Val in Bad). The manual choice of Phe was included to explore
whether removing this hydrogen bond would provide specificity.
Selecting degenerate codons for the designed library
At each designed position i, we defined two quantities for each degenerate codon j: (1) the
size, sy, which is the number of unique trinucleotides within codon j. (2) ny, the number of "non-
disruptive" residues encoded by codon j. The codons were pre-filtered by the following two
criteria: (1) The native amino acids and all "specificity residues" at the position must be encoded
by the codon. (2) Codons encoding only the native amino acid were eliminated. (3) Among the
pool of degenerate codons passing the first two criteria, any codon with a larger sy but a smaller
ny than another within the pool at position i was eliminated. This process was repeated for every
pair of codons until no codon was "dominated" by another. Optimization of degenerate codon
combinations, out of the remaining pool of codons J at each designed position i, was performed
by solving the following integer linear programming problem:
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Max ELaj cy log(ny), under Eier cy log(sy) <= 7, and .,j cy = 1 for each position i
Where cy = 1 if codonj was picked at position i, and 0 otherwise. For the winner codonj picked
at each position i, llog(nu) = log(Hing) is the logarithm of the number of unique protein
sequences encoded with all designed positions occupied by non-disruptive residues, and Elog(sg)
= log(Hisy) is the library size (or the number of unique DNA sequences in the library) as
described in the text. The problem was solved using the glpsol solver in the GLPK package
(GNU MathProg). Note that occasionally multiple codons at one position could have identical
statistics and all be optimal under this formulation, and in this case we manually examined the
choices and selected one codon.
To design the 2nd library, a "degenerate codon pair" was considered in addition to individual
degenerate codons at each designed position. This provided greater flexibility in sampling
desired sequence features within a fixed library size. A "degenerate codon pair" was defined as
two degenerate codons that are orthogonal to each other, i.e. there is no overlap between the tri-
nucleotides specified by the two codons. Experimentally, a designed position can be constructed
as a codon pair simply by mixing oligonucleotides, or by mixing the PCR products generated by
using each of two individual degenerate codons at a site (chosen in this study). The size, sy, for a
pairj is the sum of its two codon components, and the experimental mixing ratio is simply the
ratio of the sizes for the two codons. The metric n, is the total number of unique non-disruptive
residues from the two components. The filtering process as described above can be performed
for a "codon pair" separately from normal codons. We imposed an additional filtering criterion
to exclude any stop codons. For the optimization process, each designed position could be
encoded as a single degenerate codon or a pair of codons. However, to avoid an explosion of
steps in the library construction protocol, additional constraints were imposed to ensure that no
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more than one designed position was encoded by a "codon pair" within the same oligonucleotide
in the PCR based assembly procedure (Table 3.9)
ZiLjci cp py <= 1 for all position i randomized on the same oligonucleotide
where py is 1 if j is a codon pair at position i and 0 otherwise. The criterion for deciding which
designed positions were encoded by the same oligo was described later. The same ILP
optimization procedure was then solved with the above constraints to obtain the second designed
library.
Cloning, protein expression and purification
For yeast surface display, the human Bcl-xL gene (1-209), followed by a GGGGSG linker
and a C-terminal myc tag (give sequence), was cloned into the pCTCON2 vector via NheI and
BglII sites, with the gene fused in frame to the C-terminus of Aga2p with a (GGGGS) 3 linker.
PCR amplification of the Bcl-xL gene was performed using a previously made MBP Bcl-xL
fusion as the template. For recombinant proteins used in the fluorescence polarization assay, the
Bcl-xL gene and variants obtained from screening were cloned into a modified pDEST17 vector
via BamHI and XhoI sites. A BamHI cut site was present in the Bcl-xL gene, and therefore either
a BglII or a BclI site, both compatible for ligation to a BamHI cut vector, was included in the
primers for PCR amplification. Mutants of either the Bcl-xL gene or the L2-7-Al design were
made using PCR based sited directed mutagenesis followed by blunt end ligation40 , or Quick
change (Agilent). Recombinant human BH3 peptides (Bim-28, residues 142-169; Bad-28,
residues 104-131; other BH3 28-mers, Table 3.6), with a C-terminal GG linker followed by a
Flag tag sequence (DYKDDDDK), were constructed by gene synthesis. Primers were designed
using DNAWorks 41, and a two-step PCR procedure was used for annealing and amplification.
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The genes were then cloned into a modified pDEST17 vector via BamHI and XhoI sites.
Recombinant Bcl-xL proteins and BH3 peptides (with a His6 tag) were expressed in E. coli
RP3098 cells. Culture was grown at 37 0C until OD ~0.4-0.9, and expression was induced by
addition of 1 mM IPTG. Purification of Bcl-xL proteins was performed under native condition
using Ni-NTA. An additional step of gel-filtration purification with a HiLoad SuperdexTM 75
column (GE) was performed for the mutants and the designed proteins because protein
oligomerization was observed for some of them. Purification of BH3 peptides was performed
under denaturing condition using Ni-NTA and followed by reverse-phase HPLC and their
masses subsequently verified by MALDI spectrometry.
Making combinatorial libraries
The oligonucleotides introducing diversity for the two designed libraries are shown in Table
3.9. PAGE-purified oligonucleotides were ordered from Integrated DNA Technology. Two
randomized positions were chosen to be encoded by the same oligo if the length of the constant
region between them is shorter than 15 nucleotides. The protocol to introduce degenerate codon
pairs (applicable only to the second designed library) is described under the library design
section. The first library was constructed by PCR overlap extension joining two PCR fragments,
#1-1 and #1-2. Fragment #1-2 was PCR amplified from the PCR fragment #1-2a. PCR
amplification for fragment #1 -1 introduced diversity for positions 97, 101, 104, 108 and 112
using Bcl-xL in pCTCON2 as the template. PCR amplification for fragment #1 -2a randomized
positions 126, 129 and 130 using Bcl-xL in pCTCON2 as the template, and subsequent PCR
amplification for fragment #1-2 randomized position 142 using fragment #2a as the template.
The second designed library was made similarly using PCR overlap extension joining two
PCR fragments,,#2-1 and #2-2. Fragment #2-1 was 1PCR amplified from the PCR fragment #2-la,
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and fragment #2-2 was made using PCR overlap extension joining PCR fragment #2-2a and PCR
fragment #2-2b. Fragment #2-2b was PCR amplified from the PCR fragment #2-c. PCR
amplification for fragment #2-la introduced diversity for positions 96, 101, 104, 108 and 111
using Bcl-xL in pCTCON2 as the template. PCR amplification for fragment #2-1 introduced
diversity for positions 122, 125, 126, 129 and 130 using fragment #2-1 as the template. PCR
amplification for fragment #2-2a introduced diversity for positions 146 and 195 using clone Cl
from the first designed library (in the pCTCON2 vector) as the template.
The final PCR products were co-transformed with pCTCON2 vector, cut with NheI/XhoI,
into yeast following the procedure of Chao et al.42 using a BioRad Gene Pulser.
Yeast surface display, flow cytometry analysis and cell sorting
Yeast strain EBY100 and the plasmid for yeast surface display (pCTCONT2) were a generous
gift from Dr. K. D. Wittrup (Massachusetts Institute of Technology). Yeast cells were grown
overnight at 30 'C in SDCAA media, and display of the Bcl-xL protein was induced by
switching to SGCAA media for > 12 hr following protocols described by Chao et al.42 . Induced
cells were washed with TBS (50 mM Tris, 100 mM NaCl, pH 8.0), and incubated with different
concentrations of Bim-28 or Bad-28 for 1-2 hr in TBS at -25 'C. Cells were then washed with
cold TBS and labeled with primary antibodies (anti-c-myc rabbit and anti-His mouse, Sigma) at
1:67 (anti-c-myc) or 1:100 (anti-His) dilution for 30 min - 2 hr in BSS (TBS with 1 mg/mL
bovine serum albumin) at 4 'C. After washing in cold BSS, cells were labeled with secondary
antibodies (PE conjugated anti-rabbit, Sigma and APC conjugated anti-mouse, BD Bioscience)
at 1:100 dilution for 30 min - 2 hr in BBS at 4 0C. Cells were then washed again in cold BBS
prior to analysis or sorting. The analysis was performed on BD FACSCalibur-HTS 1 (BD
Bioscience), and the sorting on BD FACSAria (BD Bioscience) or MoFlo (Beckman Coulter).
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Cells were gated by forward light scattering to avoid the analysis/sorting of clumped cells. Data
were analyzed using FlowJo (Tree Star, Inc.).
Below we described sorting of the first and the second designed libraries in more detail. The
first designed library was subjected to one round of positive sorting (gating for expression and
binding) for cells binding 10 nM Bad-28, one round of positive sorting for cells binding 10 nM
Bad-28 in the presence of 1 pM unlabeled Bim, two rounds of negative sorting (gating for
expression without binding) against cells binding 10 nM Bim-28, one round of negative sorting
against cells binding 100 nM Bim-28, and finally one round of positive sorting for cells binding
10 nM Bad. The second designed library was subjected to two rounds of positive sorting for cells
binding 1 nM Bad-28 in the presence of 1 gM unlabeled Bim, two rounds of positive sorting for
cells binding 1 nM Bad-28 in the presence of 5 gM unlabeled Bim, one round of negative sorting
against cells binding 3 pM Bim-28, one round of negative sorting against cells binding 5 jM
Bim-28, and finally one round of positive sorting for cells binding 1 nM Bad-28.
Generation of sequence frequency plot
For the first designed library, 48 individual clones from the final sorted population were
examined for binding to 1 nM Bad-28 or 10 nM Bim-28. Twenty-one clones with unique
sequences showed stronger binding signal for 1 nM Bad-28 over 10 nM Bim-28, and the
sequence frequency plot shown in Fig. 3.2C was generated from these sequences (Table 3.2). For
the second designed library, 48 individual clones from the population after two round of sorting
were examined for binding tol nM Bad-28 or 500 nM Bim-28. Twenty-eight clones with unique
sequences (Table 3.4) showed stronger binding signal for 1 nM Bad-28 over 500 nM Bim-28 and
were used to generate the frequency plot in Fig. 3.3B.
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Fluorescence polarization binding assays
Unlabeled and FITC-labeled peptides (Table 3.6) were synthesized by the MIT Biopolymers
Facility at the Koch Institute for Integrative Cancer Research. A purified 21 -mer Bad peptide
with a FITC-labeled lysine43 was ordered from Calbiochem (now EMD Biosciences). Labeled
peptides were ordered with free C-termini, and unlabeled peptides were ordered with free N and
C-termini for enhanced solubility. Synthesized peptides were purified by reverse phase HPLC
using a C18 column. All assays were performed in assay buffer (50 mM NaCl, 20 mM Na2HPO4,
1 mM EDTA, 0.0 1% Triton X-100, and 5% DMSO) 4 3 at ~25 'C. For direct binding assays, the
concentration of the fluorescently labeled peptide was fixed at 5 nM. Serial dilution of the Bcl-
xL protein or its variants was performed before mixing with the fluorescently labeled peptide.
The reaction was allowed to equilibrate for at least 1 hr. For competition assays, the
concentration of the fluorescently labeled peptide was fixed at 15 nM, and the Bcl-xL protein or
its variant was fixed at 50 nM. Serial dilution of the unlabeled peptide was performed, before
adding the mixture of fluorescently labeled peptide and the Bcl-xL protein or its variant. The
reaction was allowed to equilibrate for at least 3 hr. Different fluorescently labeled peptides were
used for experiments involving different Bcl-xL protein variants in order to obtain Kd values that
could be fitted reasonably (Fig 3.4, Table 3.7). Non-binding 96 well plates (Coming
Incorporated) were used for all assays. Anisotropy measurements were performed on a
SpectraMax M5 (Molecular Devices) plate reader. All measurements were done in duplicates.
The averaged values were plotted, along with error bars signifying the spread of the two
measurements. Complete models for fitting Kd values for both direct binding and competition
experiments were described before44, and the Kd values were fit using Matlab (Mathworks). A
lower baseline corresponding to the measured anisotropy value of the free fluorescently labeled
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peptide in solution was enforced in the fitting for competition experiments for competitor
peptides failing to reach close to complete inhibition at the highest concentration.
Table 3.9 Oligonucleotides introducing randomization
Oligonucleotides Positions
randomized
1 st library 5'-GCTGTCCCTGGGGTGATGTGCAHCTGGGATGTAVBGTCA F97, Y101, A104,
CTGAAMNHCCGCCGAWRCCGCAGTTCMAWCTCGTCGCCTG L108, L112
CCTCCCTC-3' (reverse)
5'-CACATCACCCCAGGGACAGCATATCAGAGCTTTGAACAG V126, E129, Li30
RBKGTGAATRHAVTCTTCCGGGATGGGGTAAACTGG-3'
5'-TTCCGGGATGGGGTAAACTGGGGTCGCATTGTGRSCTTTT A142
TCTCCTTCGGCGGGGCAC-3'
2 nd 5'-CTGTCCCTGGGGTGATGTGCAAMNBGGATGTCASGTCACT E96, Yi01, A104,
library GAATGCCCGCCGATRCCGCAGTTCAAATHSGTCGCCTGCCTC L108, Qi1
CCTCAGC-3' (reverse)
5'-CTGTCCCTGGGGTGATGTGCAAMNBGGATGTCASGTCACT
GAACATCCGCCGATRCCGCAGTTCAAATHSGTCGCCTGCCTC
CCTCAGC-3' (reverse)
5'-CGACCCCAGTTTACACCGTCCCGGAAGAKTWCATTCACT S122, Q125, V126,
RCADHTTCAAAGDNCTGATATGCTGTCCCTGGGGTGATGTG E129, Li30
CAA-3' (reverse)
5'-CGACCCCAGTTTACACCGTCCCGGAAGAKTWCATTCACT
RCTHSTTCAAAGDNCTGATATGCTGTCCCTGGGGTGATGTG
CAA-3'
5'-CTTCCGGGACGGTGTAAACTGGGGTCGCATTGTGGGCTTT F146
TTCTCCTTSGGCGGGGCACTGTGCGTGG-3'
5'-CTTCCGGGACGGTGTAAACTGGGGTCGCATTGTGGGCTTT F146
TTCTCCGCTGGCGGGGCACTGTGCGTGG-3'
5'-CTCTCGGCTGCTGCATTGTTCCCGWAGAGTTCCACAAAAG Yl95
TATCCCAGC-3' (reverse)
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Chapter 4
Investigation and design of BH3 binding specificity toward different
anti-apoptotic Bcl-2 proteins
Portions reprinted with permission of Elsevier B.V. from:
Dutta, S., Gulla, S., Chen, T. S., Fire, E., Grant, R. A. & Keating, A. E. (2010).
Determinants of BH3 binding specificity for Mcl-i versus Bcl-xL. J Mol Biol 398,
747-62.
Portions of this chapter will be combined with other work done by Dr. Sanjib
Dutta into a manuscript to be submitted later.
Collaborator notes:
Sanjib Dutta initiated the project, performed all yeast surface display experiments,
and contributed a significant portion to all major sections in this chapter. Stefano
Gulla and Emiko Fire performed the SPOT array experiments. Bob Grant assisted
in solving the crystal structure of the complex between Mel-1 and a Mcl-1 specific
peptide.
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Introduction
In the previous chapter I described how altering the sequence of the anti-apoptotic protein
Bcl-xL affects its interaction specificity profile against different BH3 peptides. In this chapter, I
investigate how sequence changes within the BH3 peptides influence their interaction specificity
towards different anti-apoptotic proteins. Together, these studies contribute to on-going efforts in
the Keating lab to broadly determine the factors that control binding specificity in the Bcl-2
family.
BH3-only proteins exhibit diverse binding specificities for anti-apoptotic Bcl-2 proteins.
These are often measured using short peptides corresponding to the BH3 region of BH3 -only
proteins, for which the affinities of different anti-apoptotic proteins range over 10,000-fold. Most
promiscuous are Bim and Puma, which bind to the five human anti-apoptotic proteins with
dissociation constants in the low nanomolar range. In contrast, Bad and Noxa exhibit distinct
preferences for some Bcl-2 proteins over others. Noxa derived peptides (denoted as Noxa-BH3)
bind Mel-1 and Bfl- 1 with nanomolar affinity but show no detectable binding (> 100 pM) to
other prosurvival family members. Conversely, Bad-BH3 binds with high affinity to Bcl-xL,
Bcl-2, and Bcl-w but not to Mcl-1 or Bfl-12 ,3 ,4 . Mechanistically, selective binding profiles mean
that only certain combinations of BH3 -only proteins are able to kill cells 2 . The distinct binding
characteristics of the prosurvival proteins are also relevant for small-molecule therapies that
target them. ABT-737, the most effective known inhibitor, is selective for binding to Bcl-xL,
Bcl-2, and Bcl-w and has been shown to bind at the same site as the BH3 peptides6 . However,
cancers that rely on Mcl-1 to evade apoptosis are resistant to ABT-737 and related molecules7 .
Despite the importance of specificity in both the mechanism and the treatment of apoptotic
misregulation in cancer, the sequence and structural determinants of binding specificity in Bcl-2
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family members are still not completely understood. A number of studies have systematically
addressed determinants of BH3 peptide binding to prosurvival Bcl-2 family members, and a few
have addressed differential interactions with Bcl-xL versus MCl- 16,8,9. Alanine and hydrophile
scanning studies have been used to examine the effects of substitutions in several BH3 domains
on binding to different anti-apoptotic proteins6 ,8,9,io,'. Strikingly, it has been demonstrated that
Bim-BH3 variants with two or even three alanine mutations at conserved hydrophobic positions
maintain high affinity for binding to Mci-I while losing binding affinity for Bcl-xL 9. Guided by
data generated from alanine and hydrophile scanning, Boersma et al.8 combined pairs of point
substitutions in Bim-BH3 to give peptides with nanomolar affinities for Mc- 1 that discriminated
against Bcl-xL and vice versa. These mutants achieved >1000-fold specificity in the case of McI-
1 binding and >100-fold specificity in the case of BclxL binding. These studies offered valuable
insights into substitution effects in Bim-BH3.
In this chapter I describe studies using a position specific scoring matrix (PSSM) model
directly derived from experimental SPOT array data 12 to study interaction specificity of BH3
peptides against different anti-apoptotic proteins. I first discuss how this simplified model,
despite some apparent limitations, can provide insight into the sequence determinants of protein-
protein interaction specificity. A significant amount of the analysis presented in this chapter is
related to work done using yeast surface display to screen for novel BH3 sequences specific for
Bcl-Xl over Mcl-1 or vice versa, and details of this can be found in Dutta et all. Here, I describe
my own efforts to develop and use PSSM models to design libraries of BH3 sequences to be
screened for novel interaction specificity against different anti-apoptotic Bcl-2 proteins. I focus
on how the limitations of the PSSM models affect decisions made for library design, and I
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propose a design framework related to the one described in the previous chapter to cope with
these limitations.
Results
SPOT array
Dr. Stefano Gulla carried out a substitution analysis of Bim-BH3 peptides in which 10
interface positions were mutated, one at a time, to all amino acids excluding Cys and Met (Fig.
4.1). SPOT arrays displaying 26-residue Bim-BH3 variants were constructed using solid-phase
synthesis. Six hundred peptides were printed per membrane of 4 in. x 6 in., allowing the
qualitative measurement of binding of hundreds of unique peptides simultaneously. Membranes
of 200 spots each, including 170 Bim-BH3 variants, were probed with either 100 nM or 1 gM of
Bcl-xL, Bcl-2, Bcl-w (only 100 nM), Mcl-I and Bfl-1. The overall reproducibility of the data can
be seen in the first column of each array, where every sequence is a repeat of the native. Good
reproducibility was also observed for several mutant sequences that appeared two to three times
on the membranes. Trends observed using 100 nM probe concentration were reproduced at the
higher 1 IM concentration. For Bcl-xL and Mcl-1, additional interactions also become apparent
at 1 jtM, which is less true for Bfl-1 and Bcl-2. Additionally, Bcl-xL and Mcl-I SPOT results
agree qualitatively with previously reported binding studies for point mutations made in Bim-
BH3 peptides and with a prior saturating substitution analysis at the 3a and 4a positions carried
out using a phage ELISA technique6 . No such comparison was made for the Bcl-2, Bcl-w and
Bfl-1 SPOT results due to a relative lack of existing binding data between Bim-BH3 peptide
mutants with these anti-apoptotic proteins in the literature.
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Figure 4.1 SPOT array substitution analysis of Bim-BH3 peptides binding to different anti-
apoptotic proteins
(A) Bcl-xL, (B) Mcl-1, (C) Bfl-1, (D) Bcl-2, and (E) Bcl-w. The left and right panels used 100
nM and 1 pM of protein, respectively (except for Bcl-w, for which only a single experiment
under 100 nM was performed). All spots in the leftmost column of each membrane show binding
to the wild-type Bim-BH3 peptide. All other spots are point substitutions or a single repeat of the
wild-type sequence in each row, with rows defining residue positions and columns indicating
residue identities.
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PSSM model building
Using SPOT data from the Bim-BH3 substitution analysis, we developed a position-specific
scoring matrix (PSSM) to capture sequence features characteristic of binding to different anti-
apoptotic proteins. We defined the score for amino acid i at position j binding to a specific anti-
apoptotic protein R, SRg, by taking the logarithm of the fluorescence intensity for the
corresponding Bim point mutant normalized to the wild-type Bim intensity on the membrane.
PSSM models were built for all 5 anti-apoptotic proteins, and only positions and amino acids
covered by the SPOT analysis were included in the model. Different varieties of the PSSM
models were also derived by averaging the scores obtained from SPOT membranes probed under
different anti-apoptotic protein concentrations, or from additional experiments. Such models are
described in more detail below.
Analysis of experimentally selected specific BH3 sequences using PSSM model
A previous study in our lab performed by Dr. Sanjib Dutta identified a diverse set of BH3
sequences that are specific for binding Bcl-xL over Mel-I and vice versa, as well as sequences
that bind both Bcl-xL and Ml-1 (Fig. 4.2, Table 4.1, 4.2, 4.3)1. The sequences were obtained
from yeast surface display screening of a library of Bim-like BH3 sequences, with 6 positions
being randomized. These 6 positions (2d, 3a, 3b, 3d, 3f, 4a) were a subset of the 10 positions
probed on the SPOT array. These sequences provide an independent dataset to test our Bcl-xL
and Mel-i PSSM models.
We used the PSSM to score each of the sequences isolated in yeast-display screening by
summing score contributions from the six variable positions. As shown in Fig. 4.3E, this simple
model does a good job separating sequences with different binding properties. Most of the Bcl-
xL-specific sequences had high Bcl-xL scores and low Mel-1 scores, whereas the Ml- 1-specific
130
sequences had low Bcl-xL scores and a range of Mcl-I scores. Sequences of peptides that bound
to both Mcl-I and Bcl-xL generally had high Bcl-xL and Mcl-I scores. Overall, the analysis
shows that information about binding specificity for single-point mutants of Bim-BH3, as
captured by the SPOT experiments, can be used to describe the specificities of the engineered
sequences with a simple, linear model.
A4B
2
1 .
0.
W.T. Bim-BH3
Pre-screening
2d 3a 3b 3d 3f 4a
B Mci-1 specific
4
2d 38 3b 3d 3f 4a
C BcI-x,. specific
4-
03-
2d 36 3b 3d 3f 4a
D Mci-1 and Bc-xL
4-
2d 36 3b 3d 3f 48
Figure 4.2 Sequence logos for sequences with different types of specificity identified from
yeast surface display.
(a) The starting library prior to sorting with composition weighted by codon degeneracy; wild-
type Bim residues are boxed at the top. (b) Mcl-I-specific peptides. (c) Bcl-xL-specific peptides.
(f) Peptides that bound to both Bcl-xL and Mcl-1.
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Table 4.1 Bcl-xL specific sequences identified from the yeast surface display screen
Clone Position
XD5
XD6
XB9
XD9
XG12
XB6
XC5
XD2
XG1O
XD8
XD1
XB3
XF7
XF8
XG4
XF 10
XB12
XE3
XH11
XA12
XC4
XF 12
XH7
XE6
XC6
XG2
XB1O
XC9
XA2
XD4
XA7
XB4
XF9
XB8
XC12
XE4
XF1
XH8
XAl
XC10
Position Position
3d 3f2d
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
F
F
F
F
F
V
V
V
V
V
V
V
V
I
I
Y
Y
Y
F
F
F
V
V
V
V
I
I
Y
Y
Position
3a
L
L
L
L
L
I
I
I
I
V
A
L
L
L
L
L
L
L
L
F
F
F
F
F
F
L
L
L
L
I
A
L
L
L
F
F
F
L
L
L
Position
3b
R
R
Q
G
G
R
G
Q
R
K
K
K
R
K
R
S
S
K
K
Q
K
R
G
Q
Q
G
K
K
K
R
R
S
G
G
G
K
Q
Q
R
G
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Position
4a
F
Y
F
Y
F
F
F
F
F
Y
F
A
Y
Y
F
F
F
F
F
F
Y
F
F
Y
Y
F
F
N
N
F
F
Y
F
Y
F
T
Y
Y
Y
Y
N D
D D
N D
N D
D D
F D
Y D
D D
D D
Table 4.2 Mcl-1 specific sequences identified from the yeast surface display screen
Clone Position Position Position Position Position Position
2d 3a 3b 3d 3f 4a
MA5 F V N I D V
MA9 F V G I D V
MC10 F V G I D I
MB2 F I D I D V
MF12 F I E I D V
MG1 F F S I D V
MB1 I I D I D V
MB9 I I G I D T
MD5 I I G I N V
MH1 I I G T D V
MC3 I I D I N I
ME9 I I N V D I
MH11 I I D I D T
MC11 I I D I D F
MG2 I I R I E Y
MA7 I V D I D V
MAll V V D I D V
MG10 V I E I D V
MD6 V I E I N V
MG6 V I N V D V
ME6 V I N I E I
MA3 V I G I N I
MB1O V I G I D T
MH6 V I D V D I
MD7 V I R V D N
MH2 V L G T D V
MF11 V L E I E V
MA1 Y V Q I D V
MA6 Y L E I D V
MF2 Y I N I D V
MH9 A I R I D S
MB7 A I R I D N
MB11 D L G I D V
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Bcl-xL and Mcl-1 identified from the yeast displayTable 4.3 Sequences binding both
screen
Clone Position Position
2d 3a
WT I L
PA3 V L
PA5 V L
PB5 V L
PB12 V L
PC5 I L
PD2 V L
PD7 I I
PD11 Y I
PE2 V L
PE4 I I
PE12 I L
PF3 I F
PF6 I F
PF8 V L
PG4 V L
PH12 Y I
Position
3b
R
Q
R
R
G
R
K
Q
R
G
R
R
Q
R
G
R
R
Position
3d
I
V
I
I
I
F
I
V
I
I
I
I
I
I
I
I
I
Position
3f
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
Combinatorial library SPOT array
To explore sequence space more broadly, Dr. Sanjib Dutta synthesized combinatorial library
SPOT arrays. We identified residues that occurred with high frequency in selected sequences
from the yeast-display screening in our previous study: Ile (wild type), Ala, and Phe at position
2d; Leu (wild type), Ile, Phe, and Ala at position 3a; Arg (wild type) and Asp at position 3b; Ile
(wild type), Phe, Asp, Asn, and Ala at position 3d; and Phe (wild type), Val, and Asn at position
4a. From this reduced library, we synthesized all 360 possible sequences. The resulting
membranes, referred to here as library arrays, were probed with 100 nM Mcl-1 or Bcl-xL. Some
interactions of interest are shown in Fig. 4.3A and 4.3B, and the whole library array can be found
in Dutta et al.1 . The library arrays included a wider range of sequence contexts and highlighted
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Position
4a
F
V
I
F
Y
I
Y
I
V
V
F
V
I
V
V
Y
I
specificity-determining residues not evident in the Bim-BH3 substitution arrays. This was
valuable for model building and interpretation (see below).
Further improvement of the PSSM model for Bcl-xL and Mel-i
The initial PSSM model performed well, and we explored simple ways in which it could be
improved. Although we currently lack the large amount of quantitative data required to describe
synergy between peptide positions, even simple PSSM models can potentially be improved by
obtaining better estimates of single-position effects. Therefore, we used data from the library
arrays to construct a second PSSM, which allowed us to derive mutational scores averaged over
multiple contexts for some key substitutions. Evaluating substitutions in multiple contexts also
provided a larger dynamic range for the assay. Using the revised PSSM model, we obtained
better separation of scores on the Mcl-1 binding axis (Fig. 4.3F). Notably, the percentage of Mel-
1-specific peptides having Mel-1 scores higher than the highest-scoring Bcl-xL-specific peptide
along this axis increased from 33% to 85%. Much of this change was attributable to a
significantly more favorable score for Val at 4a binding to Mcl-1, when averaged over the library
SPOT sequences. Although this was not obvious from our single-substitution SPOT arrays (Fig.
4.1B), sequences with Val at 4a exhibited significantly enhanced binding to Mcl-1 compared
with the wild-type residue Phe in the context of destabilizing mutations at other positions (e.g.,
Phe, Asp, Asn, or Ala at position 3d or Asp at position 3b) (Fig. 4.3A and 4.3B). Competition
binding assays confirmed that a Phe4aVal mutation in Bim-BH3 increased affinity for Mel-1 by
more than 10-fold (Ki of-100 pM) while reducing affinity for Bcl-xL by -30-fold (Ki of -30
nM) (Fig. 4.3C and 4.3D)
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Figure 4.3 A model built using the SPOT array data captures the specificities of sequences
identified using yeast display.
(A and B) A section of the library arrays showing position 4a substitutions. (A) Each boxed set
of three spots shows substitution at position 4a with Phe, Val or Asn. Mutations were made with
different residues at position 3d, as indicated, with all other residues identical to wild-type Bim-
BH3. SPOTS in the top or bottom rows were probed with 100 nM Mcl- 1 or 100 nM Bcl-xL,
respectively. (B) Same as (A) but for mutations made in the context of Asp at 3b. (C) Effect of a
Phe-to-Val substitution at position 4a in Bim-BH3 on binding to Ml-I (C) or Bcl-xL (D) in
fluorescence competition binding assays as described in Dutta et all. (E) Engineered BH3
peptide sequences from the yeast screen were scored using a PSSM based on the Bim-BH3
substitution array data. The points plotted correspond to: Mcl-I specific peptides (red circles),
Mcl- 1 specific peptides with Val at position 4a (red filled circles); Bcl-xL specific peptides (blue
squares), peptides that bound to both proteins (green triangles). (F) The same plot constructed
with a PSSM that included the SPOT library array data; this model gave better separation of
Mcl-I binders vs. non-binders along the Ml-I score axis.
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Bfl-1 library design
The goal for this part of the study was to design BH3 libraries to be screened by yeast surface
display for sequences that are specific for one anti-apoptotic protein over all others. We started
by designing a library to be screened for sequences showing binding specificity for Bfl-1 over
Bcl-xL, MCl-1, Bcl-w and Bcl-2, guided by the PSSM models derived from SPOT array results
for the 5 anti-apoptotic proteins. For Bel-xL and Mcl- 1, we used the revised/improved PSSM
model as described in the previous section. For Bfl-1 and Bcl-2, PSSM scores were obtained by
averaging the scores derived from SPOT membranes probed under 100 nM and 1 gM
concentration of the anti-apoptotic proteins. For Bcl-w, the PSSM scores were derived from the
membrane probed with a concentration of 100 nM Bcl-w. We then defined two classes of
residues, non-disruptive and specific, at each designed position according to their PSSM scores.
A residue was defined as non-disruptive if its Bfl-1 PSSM score was among the top 50% of the
Bfl-1 scores for all amino acids across all position on the membrane. A non-disruptive residue
was further classified as specific if the difference of its Bfl-1 PSSM score with the PSSM score
for another anti-apoptotic protein was greater than logio(1.5) and ranked among the top 33% of
all such differences for all amino acids across all positions. Four types of specificity residues
(Bfl- 1 over Bcl-xL, Bfl- 1 over Mcl-1, Bfl- 1 over Bcl-2 and Bfl- 1 over Bcl-w) were defined
accordingly.
Next we chose degenerate codons at each designed positions to enrich the library with the
non-disruptive and specific residues defined above. We wanted to enrich the library with two
types of combinatorial diversities: (1) Diversity from all designed positions occupied by non-
disruptive or native residues and (2) Diversity from all designed positions occupied by specific
or native residues. We formulated an optimization procedure based on integer linear
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programming (ILP) to maximize the product of the number of these two combinatorial
diversities under a constraint of library size of 107 , a conservative number for adequate
experimental coverage of the library when doing yeast surface display. The optimization also
favored selection of degenerate codons encoding all types of specific residues available at a
designed position, and ones encoding amino acids with greater chemical diversity. A more
detailed description of the optimization procedure can be found in Materials and Methods. The
resulting optimized library is shown in Table 4.4.
Table 4.4 Bfl-1 library design results
Non-disruptive vs. Bel-xL vs. Mci-1 vs. Bcl-2 vs. Bcl-w residues encoded
residues
12d ACFGHIKMLPRTV - WKY - - FIKLMNYZ (WWK)WY
A2e ACGHPS HS H - ADHPSY (BMT)
E2g ACDEFGHIKNQRST Y FGHIKV GT CDEFGIKLMNRSVWYZWY Y (DDK)
L3a FILMNV NV N N N DHILNV (VWC)
R3b AKQR - - Not randomized
13d ACFGHIMKLNQRST _ AFGHKN _ ACDFGHILNPRSTVYVY QRSTVY (NNT)
G3e G - - - Not randomized
D3f D - - - Not randomized
E3g ACDEFGHIKLMNQ AFHIKLN AFILWV FIKLRV - AEIKLPQTV (VHA)
Eg RSTVWY RQTW Y WY EKPT(VA
Y
F4a ACFGHIKLMNQRST AGHIKL K KR CFIKLMNRSWYZVWY QRSTW (WDK)
For each position, non-disruptive residues (second column) and residues predicted by the PSSM
models to favor binding to Bfl- 1 over the indicated anti-apoptotic protein (the next four columns)
are listed. The final column shows residues included in the designed library (encoded by the
degenerate codon in parentheses), as optimized using the ILP framework.
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Bcl-xL/Bcl-2/Bcl-w library design
To identify sequences specific for each of Bcl-xL, Bcl-2 and Bcl-w, I designed a single joint
library instead of 3 separate libraries. This is because the Bcl-xL, Bcl-2 and Bcl-w sequences are
highly similar to one another within the interface region. The idea was to enrich a library in
sequences that would bind these three receptors in preference to Mcl-I and Bfl- 1, and also to
include sequence elements predicted to favor Bcl-xL, Bcl-2 or Bcl-w individually. Predicted
non-disruptive residues for this library were predicted based on the Bcl-xL PSSM. At all
positions, we approximated the predicted specificity of Bcl-xL/Bcl-w/Bcl-w over Mcl-I and Bfl-
1 as the PSSM predicted specificity of Bcl-xL over Mcl-I and Bfl-1. Specificity among Bcl-
xL/Bcl-w/Bcl-2 was predicted only for Bim BH3 positions 2g, 3a, 3d, and 3g. These 4 positions
were selected because they contact positions occupied by different amino acids among Bcl-
xL/Bcl-w/Bcl-2 when aligned to the Bcl-xL/Bim complex crystal structure (PDB ID 3FDL). The
design procedure was otherwise similar to that for Bfl-1 library design, and is described in more
detail in Materials and Methods. The resulting optimized library is shown in Table 4.5.
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Table 4.5 Bcl-xL/Bcl-2/Bcl-w library
Non-disruptive vs. Mci-1 vs. Bfl-1 intra residues encoded
residues
I2d ACEFGHIKLMNPQR HKQRY EHS - DEFGHIKLMNQRSVWSTVWY YZ (NDK)
A2e ACGPS - - - A
E2g ACDEGHIKLMNQR AHKNR W AFGILT CDEFGIKLMNRSVWYZSTVWY WV VWY (DDK)
L3a AFILMY Y Y AY ADFHLPSVY (BHC)
R3b ACGKQRST - AK IS AEGIKLRSTVZ (DNA)
ACDEFGHIKLMNQ ADEFGH DEG EN ACDEFGIKLMNRSTVW13d RSTVWY KLNQRS W E YZ (DNS)RSTVWYT VWY
G3e ACGS A A - AG (GSC)
D3f D - Not randomized
E3g ACDEGHKNQRS - - - EGQR (SRA)
F4a AFILMNQSTVWY - Not randomized
For each position, non-disruptive residues (second column) and residues predicted by the PSSM
models to favor binding to Bcl-xL over the indicated anti-apoptotic protein (the next two
columns) are listed. Listed under the column "intra" are residues that are either "Bcl-xL over
Bcl-2", "Bcl-xL over Bcl-w", "Bcl-2 over Bcl-xL", "Bcl-2 over Bcl-w", "Bcl-w over Bcl-xL", or
"Bcl-w over Bcl-2" specific. The final column shows residues included in the designed library
(encoded by the degenerate codon in parentheses), as optimized using the ILP framework.
Screening
Screening of both libraries is being conducted by Dr. Sanjib Dutta using yeast-surface display
techniques, as in Dutta et al. Successive rounds of selection for binding to the desired target in
the presence of competitors have enriched certain sequences. Analysis of these, and of the
success of the design strategy, will be included in a future joint publication.
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design results
Discussion
The PSSM model introduced in this chapter is arguably one of the simplest experimentally
parameterized models. The ability to probe interaction between more than 200 mutant peptides
and an anti-apoptotic protein in a single experiment provides a cost-effective, facile way to map
the peptide sequence space comprehensively. However, there are many limitations with such
models, arising from the SPOT experiment itself and the formulation. First of all, neither the
SPOT experiment nor the model derived takes into account any interactions among different
BH3 peptide positions. Secondly, the SPOT results are semi-quantitative at best, due to issues
such as variation of the peptide synthesis yield on the membrane, the dynamic range of the signal,
and non-equilibrium conditions. Below I suggest how, despite these caveats, it is still possible to
obtain useful insights into the relation between sequence and interaction specificity, especially
when combined with other experimental data, including the yeast display selected sequences
(Table 4.1, 4.2, 4.3) and the library SPOT arrays described in Results. I focus in the analysis
below on the PSSM models for Bcl-xL and Mcl-1, as these are the two anti-apoptotic proteins
for which we have the appropriate data for analysis. In the end we shift the discussion to library
design based on such models.
Analysis of experimentally selected sequences using the PSSM model
We used the substitution arrays to construct a PSSM and showed that this model can separate
Ml- 1-specific sequences from Bcl-xL-specific sequences and from sequences of peptides that
bind with high affinity to both receptors (Fig. 4.3E). Thus, although we cannot rule out
synergistic effects between positions in Bim-BH3 that may influence binding, much of the
specificity observed in the sequences identified from yeast-display screening can be explained by
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a simple, linear, and additive model. Importantly, this model was derived independent of
knowledge of these sequences.
To see if the Bim-BH3-based PSSM could be improved, and to explore the effects of point
mutations in the context of sequences selected from the yeast-display library rather than Bim-
BH3, we used the library arrays (Fig. 4.3A and 4.3B). The PSSM model built using data from the
library arrays was similar to that based on the Bim-BH3 substitution analysis, but it did a better
job of discriminating high-affinity versus low-affinity binding to Mcl-i (Fig. 4.3F). We traced
this effect largely to the role of stabilizing mutations at position 4a and confirmed using solution
binding studies that Val at this site is stabilizing relative to wild-type Phe for Mcl- 1 binding (Fig.
4.3C and 4.3D).
The two PSSM models differed in two ways: First, the library arrays allowed us to evaluate
the effects of key point substitutions using average values collected over many Bim-like
sequences. These averages may provide better estimates of the influence of mutations in the
engineered peptides, and the larger numbers of measurements also make them less sensitive to
noise. Second, the high affinity of native Bim-BH3 for Mel-I and Bcl-xL saturates the signal in
the SPOT arrays for many sequences and thus masks the effects of stabilizing mutations.
Because of this, the Bim-BH3 substitution array matrix incorrectly assigned similar weights to
Val and Phe at position 4a for Mcl-I binding. Our work indicates that both the concentration
used for the SPOT experiments (compare the left and right panels for Fig. 4. 1A and 4. 1B) and
the sequence context in which mutations are made (Fig. 4.3A and 4.3B) can be important for
providing appropriate mutational data to parameterize a predictive model.
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Mechanism for Bcl-xL vs. Mcl-1 specificity
Using the SPOT data as a guide, we investigated the mechanisms used to establish interaction
specificity in the peptides identified by the previous yeast surface display screen referred to in
this study. We defined three classes of substitutions according to interaction weights from the
arrays (Table 4.6). Class 1 and class 2 substitutions were specific for one anti-apoptotic protein
over another. The difference between these two classes is that class 1 substitutions retained
strong binding to the desired target on the arrays, whereas class 2 substitutions achieved
specificity at the expense of some stability. Class 3 substitutions were highly destabilizing for
binding to both anti-apoptotic proteins, without any discernable preference. Interestingly, most of
the substitutions identified as class 1 based on the arrays were highly represented in the specific
sequences identified by yeast display screening.
Many class 1 substitutions occurred in position 3d or 4a. At position 3d, both Mcl-I-specific
sequences and sequences of peptides that bound both anti-apoptotic proteins were largely
constrained to the wild-type Bim residue Ile (Fig 4.2B). In contrast, sequences specific for Bcl-
xL spanned a range of residues, including polar residues, but never Ile (Fig. 4.2C). In co-crystal
structures of Bim in complex with Bcl-xL versus Mcl-1, the 3d site is less tightly packed in Bcl-
xL, where it is located next to a less helical a2/a3 region of the receptor; this may explain the
observed permissiveness 13. Thus, the class 1 mutations favoring Bcl-xL at 3d (Ala, Asp, Asn,
Phe, Tyr, Thr) appear to be key specificity determining factors disfavoring Mcl-I binding.
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Table 4.6 Classification of representative substitutions observed in selected sequences
according to their intensities as measured on the substitution SPOT array
Position Substitutions Class Specificity
2d F/Y la Bcl-xL
3a I la MCI-I
A 3 -
3b N la MCI-I
D,E 2b Mcl-i
3d A/D/N/F/Y/T/V la Bcl-xL
3f E/N 3C -
4a N/S/V/T/I la Mcl-i
a Normalized signal intensity for binding to one anti-apoptotic protein more than 2-fold of that of
another. Signal intensity for the preferred receptor, ;>0.7.
b Normalized signal intensity for binding to one anti-apoptotic protein more than 2-fold of that of
another. Signal intensity for the preferred anti-apoptotic protein, -0.2-0.3.
Normalized signal intensity for both anti-apoptotic proteins, <0.2.
At position 4a, the sequence logos in Fig. 4.2C emphasize that Bcl-xL is selective for large
aromatics, while Mcl-I can accommodate multiple substitutions (Fig. 4.2B), with Asn, Ser, Val,
Thr, and Ile assigned as class 1 mutations favoring Ml-I binding. The co-crystal structure of
Mcl-I with one of the Mcl-1 specific peptides, MB7, shows that Asn can be easily
accommodated at position 4al, without any significant local perturbation, in agreement with
previous observations that this site is more open and solvent-exposed in Ml-I compared with
Bcl-xL,8 ,9 14.
At position 2d, two class 1 mutations favoring Bcl-xL (Phe and Tyr) were very common in
Bcl-xL-specific sequences (Fig. 4.2C). It is interesting that the BH3 region of Bad, which is
highly specific for Bcl-xL over Mcl-1, also has a Tyr at the same position. Mutational studies in
Bad have confirmed that this residue influences binding specificity'5 . Ile at 3a is a class 1
substitution for Mcl-1, and this is prominent in the Ml- I-specific sequence logo.
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For position 3b, the sequence logo reveals relatively low information. However, the
substitutions Asn (class 1 for Mcl-1) and Glu or Asp (class 2 for Ml- 1) are present in the Mcl-1-
specific sequences and completely absent from the Bcl-xL specific sequences (Table 4.1 and 4.2).
An examination of individual sequences identified in the yeast screen shows that all contain
more than one substitution from wild-type Bim-BH3. Most Bcl-xL and some Ml- 1-specific
peptides combined multiple class 1 mutations, including Bcl-xL-specific peptide XD5 (two class
1 substitutions: Tyr at position 2d and Asn at position 3d) and Mcl-I-specific MB9 (two class 1
substitutions: Ile at position 3a and Thr at position 4a) (Table 4.1 and 4.2). Interestingly, many
Ml- 1-specific sequences combined class 1 with class 2/3 substitutions (such as Asp/Glu at
position 3b or Asn/Glu at position 3f), thereby achieving specificity but sacrificing stability.
Many of these sequences also included Val/Ile at position 4a as the class 1 mutation. Therefore,
we speculated that Val/Ile, in addition to providing specificity as class 1 substitutions, might
provide stability to compensate for destabilizing mutations. Interestingly, as shown in Fig. 4.3,
the point mutation Phe4aVal in Bim-BH3 increased Ml- 1 binding affinity and conferred a
significant preference for binding Mcl- 1 over Bcl-xL. This type of single amino-acid substitution
would be missed in the screen, which eliminated all clones that bound Bcl- xL at 1 pM
concentration. These observations point to an interesting strategy to satisfy the requirements of
the screen-that is, combining substitutions that destabilize binding for both receptors (to meet
the specificity constraint) with ones that selectively enhance binding for the receptor of interest
(to meet the stability constraint). Using the above analysis, we could rationalize the sequence
patterns for most of the specific sequences.
We would like to emphasize that the classifications and interpretations presented above are
based largely on SPOT experiments but not more rigorous quantitative measurements of binding
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affinity. Therefore, we avoid some of the more subtle issues, such as the role of substitutions that
are not clear-cut in our classification scheme, and questions about whether multiple specificity
determinants are synergistic or simply additive. Despite these simplifications, we show that a
framework based on a simple SPOT/PSSM analysis can logically explain many sequence-
function relationships that underlie the observed behavior of the specific peptides. Whereas our
model is imperfect and leaves the detailed behavior of various examples unexplained, the power
of experimental screening has nevertheless provided sequences that combine different
substitutions to achieve multiple objectives, whether these combinations follow our intuition or
have more subtle effects.
Library design
In this section I discuss the rationale behind library design guided by PSSM. I focus the
discussion on Bfl-1 library design, although the same general concepts stand for the Bcl-xL/Bcl-
2/Bcl-w library design as well.
As described before, despite evidence that SPOT PSSM models can provide insight into the
sequence determinants of interaction specificity, one should not over-estimate its predictive
power. One bottleneck preventing the SPOT PSSM models from making meaningful specificity
predictions stems from the limited dynamic range of SPOT signals. For example, it is difficult to
evaluate whether residues with strong or saturated SPOT signals enhance or weaken binding
relative to the native residue, and hence their roles in specificity. A larger number of such
residues were present on the Bcl-w, Bcl-2, and Bfl-1 membrane compared to those on Bcl-xL
and Mel-1. This could obviously reflect the possibility that Bcl-w, Bcl-2 and Bfl- 1 are on
average more tolerant of interaction with Bim BH3 point mutants. However, it could also be
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explained by different anti-apoptotic proteins simply possessing different dynamic ranges for the
SPOT signals.
Regardless of the origin, the observations noted above could complicate prediction of global
specificity for binding Bfl-1 in preference to all other 4 anti-apoptotic proteins. For example,
only a few residues were predicted to be Bfl-1 over Bcl-w specific, and it could be risky to
enforce inclusion of these residues in all library members without further verification of their
influence on binding. We therefore identified and considered all residues predicted to confer
specificity against any of the four off-target receptors. Global specificity was addressed by
requiring that the degenerate codons chosen span residues predicted to confer specificity against
each receptor when applicable (see Materials and Methods). We reasoned that this should allow
a diverse number of ways to combine residues of different specificity types from each designed
position in the library, and hopefully the screening could identify the correct combinations of the
ones behaving as predicted. The extent of inclusion of these residues was influenced by the
library size constraint, and also by the amino acid diversity of the degenerate codons available.
At the same time, even if no predictions were correct for one or more particular binary
specificity class (e.g. Bfl-1 over Bcl-w), as long as other specificity predictions were accurate to
some extent, the library would still be sampling a sequence space guided in a useful manner. A
strategy emphasizing diversity can also be rewarded by capturing important residues missed by
predictions.
In addition to enriching residues predicted to be specific according to SPOT PSSMs, we also
aimed to enrich residues showing at least moderate binding on the Bfl-1 SPOT membrane (the
non-disruptive residues). Note that because all predicted specificity residues were required to
have a specified minimal Bfl-1 SPOT signal, their inclusion was given priority in our library
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design scheme and these residues indeed dominated the designed libraries in this study (Table 1,
2). However, one could imagine, in cases where fewer specificity residues were predicted, a
more inclusive strategy could be rewarded for the same reasoning described above. Again the
extent of inclusion of such residues would be constrained by other factors such as the library size.
Materials and Methods
PSSM model
The original PSSM score for amino acid i at positionj binding to a specific anti-apoptotic
protein R, SRj, was obtained by taking the logarithm (logio) of the ratio of the fluorescence
intensity for the corresponding Bim-BH3 point mutant to the intensity of wild-type Bim-BH3
(averaged over all wild-type spots) on the membrane.
To derive the revised PSSM models for Bcl-xL and Mcl-1, we used spots from the library
array that had raw signals >106.5. To score the contribution of residue i at positionj, we
computed the log of the ratio of the average signal for peptides with residue i at positionj to the
average signal for peptides with the native Bim-BH3 residue at positionj. For residues not
included in the library arrays, the substitution array data were used. However, scores for residues
that had normalized intensities greater than 1 in the substitution arrays were reduced to 1. In
addition, the score for Ile at 4a was assigned the same value as Val at 4a because Ile was not
included in the library SPOTS and Val and Ile had similar scores from the substitution arrays.
For library design, we used the revised model for Bcl-xL and Mel-1. For Bcl-2 and Bfl-1, the
models were obtained by averaging the PSSM scores derived from membranes probed with 100
nM and 1 pM of anti-apoptotic proteins. For Bcl-w, the model was derived from the membrane
probed with 100 nM Bcl-w. In all models used for design, normalized intensities for all residues
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with values greater than 1 were capped at 1 before use in deriving the PSSM score (except for
the revised models as described above). As Met and Cys substitutions were not printed on the
membrane, their scores were defined as those of Leu and Ser respectively when predicting "non-
disruptive" residues. However, they were not scored for the specificity predictions.
Bfl-1 library design
The definition of non-disruptive residues and 4 different types of specific residues (Bfl- 1 over
Bcl-xL, Mel-1, Bcl-w, or Bcl-2) is given in the Results. In addition, Pro was removed from
consideration as a potential specific residue. Four quantities were defined for each degenerate
codonj at position i: (1) the size, sy, which is the number of unique tri-nucleotides within the
codon, (2) ndy, the number of non-disruptive residues encoded by the codon, (3) spy, the number
of specific residues (considering all 4 different types) encoded by the codon, and (4) my, the
number of "misses" in chemical diversity for the codon. The metric my was defined for codons at
positions 2d, 2g, 2a, 3b, 3a, 3d, 4a. Amino acids were divided into different classes according to
their physicochemical properties, and then the number of classes with no representation from the
amino acids encoded by the codon was counted. For the more buried positions 2d, 3a, 3d, 4a, the
classes were [A], [L], [IV], [FY]. For the more exposed positions 2g, 3b, 3g, these classes were
[AG], [DE], [KR], [NQ], [ST]. A "miss" was scored for a class only if at least one amino acid
from that class was designated non-disruptive. A codon was considered more chemically diverse
if it has a lower my.
At each designed position, we only considered degenerate codons that encode (1) the native
Bim BH3 amino acid and (2) at least one of each type of specific residue present at that position.
The set of remaining degenerate codons was trimmed further by comparing every two. If a
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degenerate codon had a larger sy, a smaller spy, and a larger my than another codon, then the first
codon was considered dominated by the second and was eliminated from the pool. The
elimination process was repeated until no degenerate codon dominated any other codon in the
remaining set. Optimization of degenerate codon combinations, out of the remaining pool of
codons J at each designed position i, was performed by solving the following integer linear
programming problem:
Max Jij 1 i cy log(ndy) + Jibe, cu log(sp.)
subject to JiLe, cy log(s) <= 7
subject to JiLy cy m <= 4
subject to L>jij cy = 1 for each position i
Where cy = 1 if codonj was picked at position i, and 0 otherwise. For the winner codonj picked
at each position i, Eilog(ndy) = log(fJindy) is the logarithm of the number of unique protein
sequences encoded with all designed positions occupied by non-disruptive residues, Eilog(spy)=
log(flispy) is the logarithm of the number of unique protein sequences encoded with all designed
positions occupied by specific residues, and Eilog(sy) = log(]-[isy) is the library size (or the
number of unique DNA sequences in the library) as described in the text. Zimy is the total
number of misses in chemical diversity across all positions and we manually picked 4 as a
threshold. The problem was solved using the glpsol solver in the GLPK package (GNU
MathProg).
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Bcl-xL/Bcl-2/Bcl-w library design
Most of the design procedure is the same as that for Bfl-l library design, with a few
modifications. "Non-disruptive" residues were defined based on the Bcl-xL PSSM. As describe
in Results, for positions 2d, 2e, 3b, 3e, 3f and 4a, only two types of specificity residues were
predicted, "Bcl-xL over Mcl-I" and "Bcl-xL over Bfl-1". For positions 2g, 3a, 3d and 3g, 6 more
types of specificity residues, "Bcl-xL over Bcl-2", "Bcl-xL over Bcl-w", "Bcl-2 over Bcl-xL",
"Bcl-2 over Bcl-w", "Bcl-w over Bcl-xL", and "Bcl-w over Bcl-2" were predicted. As for Bfl-l
library design, only codons that encode (1) the native Bim BH3 amino acid and (2) all different
types of specific residues present at each design position were considered.
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Chapter 5
Conclusions
In this thesis I showed applications utilizing both computational and experimental methods
for the design of protein-protein interaction specificity. Below I will first review briefly what we
learned from these applications, and suggest possible future improvements. To conclude, I will
suggest a general framework to combine different approaches in these studies, especially those
presented in Chapter 2 and Chapter 3, to enhance our future design capabilities.
Summary of design applications in this thesis
In Chapter 2 I used a scoring function specific for bZIP coiled coil to computationally design
a peptide inhibitor targeting the BZLF1 protein. One major question was whether the scoring
function was robust enough given the non-canonical sequence and structural features of BZLF 1.
Through the success of the design and other mutational studies, we showed that at least some of
the key specificity determinants learned from more typical human bZIP coiled coils could be
applied for this system as well, probably by making the designed model more canonical in the re-
modeled region. The demonstration of such "modularity" is encouraging for future studies that
aim to perform protein design by applying experimental knowledge obtained from related
proteins.
In Chapter 3 I used structural modeling to guide the design of a library to be screened for
anti-apoptotic Bcl-2 proteins with novel interaction specificities. I suggested an approach to
broadly include predicted non-disruptive residues in addition to specific ones, providing a
"safety net" for important residues missed by the difficult specificity predictions. To fully utilize
the power of library screening, I developed an optimization framework to maximize inclusion of
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the predicted non-disruptive residues under a constraint of library size. Analyzing specific
sequences obtained from the screening revealed that key important residues were missed by our
specificity predictions but captured by our non-disruptive residue predictions. We also showed
that contributions among different residues can be highly non-additive. As higher order
interactions among different residues can be difficult to predict, we argue that this demonstrates
the importance of allowing combinatorial possibilities to be explored among residues at different
designed positions.
Reflecting on results obtained from Chapter 3, there appear to be several aspects of the
library design approach outlined above that can be further improved upon. In using structural
models to guide library design, we relied only on the Rosetta modeling suite. Although no
current modeling protocol has been shown to be vastly superior over others in terms of
specificity predictions, examining prediction results from multiple models could potentially
remove biases generated by a single model. For example, specificity features predicted by
multiple models could be considered for inclusion with higher priority over ones predicted by
only one model. Or alternatively, one could enforce the inclusion of any specificity features
predicted by any model. However, I observed during the library optimization phase that the
constraint to include all predicted specificity residues could lead to usage of inefficient
degenerate codons, significantly compromising the inclusion of predicted non-disruptive residues.
Relaxing this constraint can potentially lead to designed libraries with better quality. This can be
done by allowing the omission of one or more predicted specificity residues, or by the approach
presented in Chapter 4 in which predicted specific residues are given more weights in the
optimization, but not necessarily always included. Finally, in this study we pre-determined the
number of designed positions before library optimization. We also enforced a hard constraint on
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library size. It would be desirable, in future applications, to carry out a more rigorous exploration
of how including different numbers of positions and relaxing the library size constraint would
affect the quality of the library, before choosing one library for screening.
In Chapter 4 I developed a PSSM model from SPOT array data and used it to analyze and
design specificity of BH3 peptides binding different anti-apoptotic Bcl-2 proteins. We showed
that despite the many deficiencies, the simplified model could nonetheless provide interesting
insights into sequence determinants of specificity. In the future, it will be interesting to
investigate whether such models can be further improved by combining terms derived from
structural modeling or from other experimental data such as library screening.
New design framework
From a more application oriented viewpoint, the bZIP coiled-coil scoring function developed
by Grigoryan et al.' and used in Chapter 2 suggested an intriguing solution to bypass the current
limitations of more general scoring functions. The function contains components derived from
structural models as well as experimental information. It is specific for use with coiled coils,
particularly bZIP coiled coils, and cannot be applied to other types of proteins. On the other hand,
the restrictive nature also allows interaction specificity to be captured with higher accuracy under
a simpler formulation, which can be incredibly useful for design. One challenge for this approach
is that the protein family of design interest might not have natural representatives that span a
diverse sequence and interaction profile space. This makes it difficult to extract information
useful for design from interaction data obtained from these proteins, using methods such as
machine learning2 ,3,4 . Taking the design application in Chapter 3 as an example, all natural
human anti-apoptotic Bcl-2 proteins bind the BH3 peptide Bim strongly. It is therefore less likely
that interaction data among natural anti-apoptotic Bcl-2 proteins and BH3 peptides will encode
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information about possible sequence determinants specific against Bim. In this regard, exploring
"unnatural" sequence and interaction space becomes necessary. One solution to address both
issues is to screen large random libraries for interaction properties not observed in nature.
However, due to the combinatorial nature of sequence space, such practice might be more
suitable for protein interfaces involving a smaller number of residues (e.g. a small protein
interacting with a short peptide)5 ,6.
In Chapter 3, I described efforts to computationally design a library of sequences, reasoning
that structural models can enhance the probability of identifying sequences with the desired
interaction specificities in a library screen. Although not explicitly demonstrated in this thesis,
such a guided library screening approach would be more efficient in creating a meaningful
interaction data set compared to screening a random library as described in the previous
paragraph. In the study in Chapter 3, we explicitly screened for and identified sequence
determinants that favored binding Bad over Bim. Interestingly, one of the specific sequences
actually displayed global specificity against other BH3 peptides, even though such specificity
was neither designed nor screened for. As discussed in Chapter 3, this could happen simply by
chance. However, it is also intriguing to think that a library design strategy guided by rather
simple principles (enriching sequences predicted to bind Bad and including predicted specificity
elements against Bim) can help enrich sequences with other types of specificity elements as well.
Obviously, this represented only a minor step toward comprehensively mapping sequence and
specificity space. Nonetheless, we can extend this approach to identify sequences specific for
BH3 peptides other than Bad. The goal of a complete understanding of the relation between
sequence and specificity is difficult to attain, but garnering information on various sequence
elements that favor or disfavor binding to each BH3 peptide can be within reach. This knowledge,
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combined with structural models that fill in the missing terms not learned from experiments, can
be sufficient for the task of designing individual sequences with other novel interaction
specificity patterns, without the need for repeated library screening efforts.
In summary, the approach suggested above consists of the following steps: (1) Use structural
modeling to make guided libraries, (2) Screen the libraries for sequences with interaction
specificities that one wants to learn, (3) Try to extract information from the screening results and
combine that with structural models to build better scoring functions, and (4) Use the better
model to design other desired interaction specificities. My thesis demonstrated the first two
points. More computational and experimental studies will be required to test the feasibility of the
latter two.
The above represents a general outline for the proposed design framework. It is likely that
one will meet different problem-specific challenges when actually going through the whole
process. One potential challenge arises if the protein interaction interface of interest is highly
flexible. Scoring functions derived from experiments usually assume an invariant set of
important contacts between certain positions at the interface (determined from available
structures of the complexes of interest), and the strength of an interaction can be estimated as the
sum of weights for these contacts. Such formulation makes it convenient to train or parametrize
weights for these contacts. However, this assumption is less valid if major conformational
changes at the interface are involved. Contacts can occur between significantly different
interfacial positions instead to generate different binding models. Such possibility should be
considered when available data is in conflict with a scoring model that dictates only one rigid
protein interface. Learning potential conformational changes from interaction data alone (point 3
above) is a great challenge, and knowledge of different binding models can be helpful. If no
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existing structural data is available, the same tools to explore backbone flexibility as describe in
Chapter 1, albeit no substitute for experimental structural data, can be used to obtain insight.
Obtaining structural data for complexes suspected to adopt different binding models can also be
extremely valuable. More sophisticated machine learning algorithms 4 can then be applied to
learn from interaction data while incorporating such information.
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